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SUMMARY

Aberrant expression of nuclear transporters and deregulated subcellular localization of their cargo proteins
are emerging as drivers and therapeutic targets of cancer. Here, we present evidence that the nuclear
exporter exportin-6 and its cargo profilin-1 constitute a functionally important and frequently deregulated
axis in cancer. Exportin-6 upregulation occurs in numerous cancer types and is associated with poor patient
survival. Reducing exportin-6 level in breast cancer cells triggers antitumor effects by accumulating nuclear
profilin-1. Mechanistically, nuclear profilin-1 interacts with eleven-nineteen-leukemia protein (ENL) within the
super elongation complex (SEC) and inhibits the ability of the SEC to drive transcription of numerous pro-cancer genes including MYC. XPO6 and MYC are positively correlated across diverse cancer types including
breast cancer. Therapeutically, exportin-6 loss sensitizes breast cancer cells to the bromodomain and extra-terminal (BET) inhibitor JQ1. Thus, exportin-6 upregulation is a previously unrecognized cancer driver
event by spatially inhibiting nuclear profilin-1 as a tumor suppressor.

INTRODUCTION
In eukaryotic cells, the nuclear membrane compartmentalizes
cellular contents into the cytoplasm and nucleus. For large macromolecules such as proteins and RNAs that exceed the diffusion limit of the nuclear pore complexes (NPCs), trafficking
across the nuclear membrane is mediated by the importin and
€ttler and Görlich,
exportin proteins in the karyopherin b family (Gu
2011). This evolutionarily conserved mechanism ensures the
presence of the cargo molecules within their destined subcellular
compartments at the levels appropriate for the specific cellular
state. However, the physiological balance of many proteins
across the nuclear membrane becomes dysregulated in cancer
via different mechanisms, including altered expression of nucleocytoplasmic transporters (Hung and Link, 2011). For instance,
tumor-suppressor proteins such as p53, FOXO2, p27, and pRb
undergo nuclear exclusion and spatial inactivation in certain cancer cells due to upregulation of their nuclear exporter XPO1/

CRM1, which shuttles hundreds of nuclear proteins containing
leucine-rich nuclear export sequences (NESs) (Gravina et al.,
2014; Hung and Link, 2011). XPO1 is a marker of poor cancer
prognosis, and its inhibition showed anticancer benefits in
various preclinical and clinical studies (Mahipal and Malafa,
2016). The XPO1-selective inhibitor Selinexor was recently
approved to treat adult patients with relapsed or refractory multiple myeloma and diffuse large B cell lymphoma (DLBCL) (Gandhi et al., 2018; Kalakonda et al., 2020).
XPO6 is the most recently discovered member of the exportin
family and is specific to the dimeric complex of nuclear actin and
€ven et al., 2003). Though capable of recognizing
profilin (Pfn) (Stu
actin alone, the affinity and export activity of XPO6 toward the
€ven et al., 2003).
actin/Pfn complex are significantly higher (Stu
Evolutionarily conserved from insects to mammals, XPO6 is
essential for Drosophila embryonic development (Perrimon
et al., 1989) yet transiently silenced in the amphibian Xenopus
oocytes prior to meiotic maturation to increase the levels of
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nuclear filamentous actin that physically stabilize their giant
nuclei (Bohnsack et al., 2006). In addition, nuclear actin in its
monomeric form regulates diverse processes including chromatin remodeling, RNA transcription, and DNA damage
response (Virtanen and Vartiainen, 2017). The consensus from
these studies is that nuclear actin positively regulates gene
expression and cell proliferation (Virtanen and Vartiainen,
2017). Consistent with this, nuclear actin depletion occurs in
growth-arrested normal breast epithelial cells but not their malignant counterparts, indicating a potentially pro-cancer effect of
nuclear actin at least in the context of breast cancer (Spencer
et al., 2011).
In contrast, the biological function of nuclear Pfn remains
poorly understood, despite its presence in the nucleoplasm, nuclear speckles, and Cajal bodies (Skare et al., 2003). As the first
actin-binding protein identified decades ago (Carlsson et al.,
1977), the role of Pfn1, the ubiquitously expressed Pfn isoform,
has been well demonstrated in cytoplasmic actin polymerization
(Jockusch et al., 2007) and underlies its essentiality for many eukaryotic organisms (Balasubramanian et al., 1994; Verheyen and
Cooley, 1994; Witke et al., 2001). Paradoxically, Pfn1 also shows
tumor-inhibitory activities in breast, bladder, and pancreatic
cancer models (Diamond et al., 2015; Wittenmayer et al., 2004;
Yao et al., 2014; Zoidakis et al., 2012; Zou et al., 2007). Our prior
study suggested that the anticancer activity of Pfn1 stems from
its poorly understood nuclear functions that are spatially separate from its essential cytoplasmic functions (Diamond et al.,
2015) and requires interaction with at least one nuclear protein
containing the poly-L-proline (PLP) motif (XP R 5; X = G, A, I,
S, L) (Holt and Koffer, 2001). However, our current knowledge
of PLP-containing binding partners of nuclear Pfn1 is limited to
p42POP (Lederer et al., 2005) and SMN1 (Giesemann et al.,
1999), neither of which has clear functional relevance to cancer.
As an essential protein rarely mutated, both the cancer relevance and underlying mechanism of Pfn1 remain unclear.
Though largely unexplored in cancer, XPO6 mRNA level is a
poor prognostic marker for prostate cancer (Hao et al., 2016).
XPO6 downregulation was detected in senescent human fibroblasts, positively linking it to proliferation (Park et al., 2011).
Here, we report that XPO6 upregulation is a prevalent cancer-associated event that serves to indirectly reduce the anticancer function of Pfn1 in the nucleus as a transcriptional
repressor while preserving its essential function in the
cytoplasm.
RESULTS
XPO6 upregulation occurs in cancer and associates with
poor patient survival
To investigate the cancer relevance of XPO6, we first examined
The Cancer Genome Atlas (TCGA) datasets. XPO6 mRNA is
significantly upregulated in 19 cancer types compared to normal
controls (1.2–1.9-fold), with thyroid carcinoma being the only
cancer type showing downregulation (Figure 1A; Table S1A). In
breast cancer, the average upregulation of XPO6 mRNA is
1.5-fold. To increase the numbers of normal samples in our
analysis, we used the combined RNA sequencing (RNA-seq)
data from TCGA and The Genotype-Tissue Expression (GTEx)
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project (Wang et al., 2018). Statistically significant upregulation
of XPO6 mRNA levels was confirmed in all 16 cancer types for
which processed data are available (Table S1B). Further analysis
of matched tumor versus adjacent normal tissues in the TCGA
dataset confirmed statistically significant XPO6 mRNA upregulation in 13 cancer types (Table S1C). For breast cancer, 86.6% of
the 112 cases with adjacent normal tissues overexpress XPO6
by a median 1.36-fold (Figure 1B). The XPO6 mRNA upregulation
occurs independently of breast cancer subtype and stage (Figures S1A–S1C). We next examined the proteomic data of a
cohort of 125 breast tumors and 18 normal breast tissue samples
in the Clinical Proteomic Tumor Analysis Consortium (CPTAC)
database. Unlike the other nuclear exportins (XPO1, 2, 4, 5,
and 7), XPO6 peptides are detected in all tumor samples but
none of the normal samples (Figure S1D), indicating their lower
protein abundance in normal breast tissues below the detection
limit.
We next examined a panel of breast cancer cell lines and two
untransformed breast epithelial cell lines (HuMEC and MCF10A).
Quantitative reverse transcriptase PCR (qRT-PCR) and western
blot showed that both mRNA and protein levels of XPO6 are
significantly higher in cancer versus normal cell lines. Similar to
patient samples, XPO6 upregulation is independent of breast
cancer subtype and occurs in both estrogen receptor (ER)-positive (MCF-7, T47D, CAMA-1) and ER-negative (MDA-MB-231,
BT-549, HCC70) cells (Figures 1C and 1D).
We next examined the correlation between XPO6 and cancer
patient survival. Using Kaplan-Meier (KM) Plotter (Nagy et al.,
2018), we first performed pan-cancer Kaplan-Meier analysis between XPO6 mRNA levels and overall survival (OS) using the
TCGA RNA-seq data. We observed a statistically significant association between high XPO6 mRNA levels and worse OS for
bladder, kidney renal clear cell, and liver hepatocellular carcinomas (Figure 1E). For breast cancer, the correlation followed
a similar trend, with the median OS of the low XPO6 group nearly
doubling the high XPO6 group despite being statistically insignificant (p = 0.22) (Figure 1E). However, statistical significance (p =
0.031) was reached among stage II patients (60% of the dataset) (Figure 1F) but not patients at other stages (Figure S2A).
Though not statistically significant, the association between
XPO6 mRNA levels and OS was preferentially detected in
lymph-node-positive patients with no clear dependence on ER
status (Figures S2B and S2C). No association between XPO6
mRNA and progression-free survival (PFS) was observed,
regardless of lymph node status (Figure S2D).
Next, we analyzed breast cancer microarray data using the
Gene Expression Omnibus (GEO) and European Genome-phenome Archive (EGA) datasets available at KM Plotter. In the combined datasets, we observed nearly significant correlation (p =
0.066) between high XPO6 mRNA levels and worse relapsefree survival (RFS) in lymph-node-positive, but not lymphnode-negative, patients (Figure S2E), and this was confirmed
using an individual dataset (GSE21653) (Finetti et al., 2008)
(Figure S2F). Statistically significant correlations between
XPO6 mRNA and RFS were detected for both ER-negative
(GSE21653) and ER-positive (GSE9195) patients in a datasetdependent fashion (Finetti et al., 2008; Loi et al., 2008) (Figures
S2G and S2H). In addition, we observed statistically significant
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association between high XPO6 protein levels and worse OS of a
cohort of 65 breast cancer patients (Tang et al., 2018) (Figure 1G),
the only proteomic dataset available at KM Plotter for outcome
analysis. Taken together, our findings demonstrate that XPO6
upregulation occurs in a large number of tumor types including
breast cancer, and this is associated with poor patient survival.
XPO6 is required for cancer cell growth
Hypothesizing that cancer cells may be addicted to XPO6, we
silenced it in three breast cancer cell lines expressing high levels
of XPO6 (MCF-7, T47D, MDA-MB-231; Figures 1C and 1D) and
the non-cancer MCF10A cells. Two XPO6 short hairpin RNAs
(shRNAs) significantly inhibited the growth of all three cancer
cell lines (Figures 2A–2C). XPO6 knockdown also inhibited the
growth of human soft tissue sarcoma SK-UT-1 and SK-LM-1
cell lines (Figures S3A and S3B). Interestingly, it showed no
growth effect on MCF10A cells, suggesting that normal epithelial
cells without XPO6 upregulation may be more tolerant of its loss.
Conversely, overexpressing XPO6 in MCF10A cells increased
their growth (Figure 2D), supporting the positive impact of
XPO6 on cell growth.
To confirm that the growth phenotype of XPO6 knockdown
was due to on-target effects, we stably expressed wildtype (WT) and RNA-inhibitor-resistant (RNAi-Res) XPO6 in
MCF-7 cells (Figure S3C). While shXPO6 #3 inhibited the
growth of XPO6(WT) MCF-7 cells, this effect was significantly
rescued by XPO6(RNAi-Res) (Figure 2E). Multiple G1/S transition markers were downregulated by XPO6 knockdown in the
XPO6(WT) cells, including p-Rb(Ser795), E2F1, and cyclin D1,
which were rescued by XPO6(RNAi-Res) (Figure 2E). Bromodeoxyuridine (BrdU) labeling of MCF-7 cells was reduced by
XPO6 knockdown (Figure 2F). DNA content analysis of synchronized MCF-7 cells further confirmed the inhibitory effect
of XPO6 knockdown on S-phase entry (Figure 2G).
Next, we implanted shLUC- and shXPO6-#3-infected MCF-7
cells expressing XPO6(WT) or XPO6(RNAi-Res) into the mammary fat pads of female nude mice supplemented with estrogen
pellets. XPO6 knockdown in the XPO6(WT) cells significantly
reduced tumor growth rate (Figure 3A), which was confirmed
by endpoint tumor weights (Figure 3B). This effect was markedly
attenuated in the XPO6(RNAi-Res) cells, and the difference in tumor volumes and weights between shXPO6 #3 and shLUC
groups was non-significant (Figures 3A and 3B). Despite the
incomplete rescue, presumably due to off-target effects of
shXPO6 #3, our data sufficiently demonstrate the tumor-inhibitory effect of XPO6 loss. Staining the tumors for Ki67 and p-

Article
Rb(Ser795) revealed that XPO6 knockdown in XPO6(WT) but
not XPO6(RNAi-Res) cells reduced proliferation (Figures 3C
and 3D), confirming the in vitro findings.
For further validation, we used CRISPR/Cas9 to knock out
XPO6 in MDA-MB-231 cells. We chose Cas9(D10A) nickase
(Cas9n) to increase editing specificity and designed four pairs
of single guide RNAs (sgRNAs) targeting XPO6. All four pairs
reduced XPO6 protein level (Figure S4A). Compared to controls,
XPO6 knockout (KO) MDA-MB-231 cells grew significantly
slower, phenocopying XPO6 knockdown in MCF-7 cells (Figure S4A). Single clones showed even stronger effects (Figures
S4B and S4C). BrdU labeling and DNA content analysis displayed evidence of G1/S arrest and cell-cycle inhibition, similar
to XPO6 knockdown effects in MCF-7 cells (Figures S4D and
S4E). Thus, our data suggest a strong reliance of breast cancer
cells on XPO6 function, which manifests at least partially through
an effect on cell-cycle progression.
Nuclear Pfn1 is required for the growth-inhibitory effect
of XPO6 loss
XPO6 is a specific nuclear exporter for the Pfn/actin complex
€ven et al., 2003). XPO6 knockdown and KO caused signifi(Stu
cant nuclear accumulation of endogenous Pfn1 (Figures 4A
and S5A). Nuclear accumulation of exogenous yellow fluorescent protein (YFP)-tagged Pfn1 was similarly induced by XPO6
loss (Figures S5B–S5D). Pfn1 is a poorly understood tumor suppressor that is paradoxically essential for eukaryotic cells. Restricting Pfn1 expression to the nucleus versus cytoplasm in
our prior study indicated that the tumor-suppressive activity of
Pfn1 stems at least in part from its nuclear functions, spatially
separate from its essential role in the cytoplasm (Diamond
et al., 2015). To test whether the anticancer effect of XPO6
loss is caused by nuclear Pfn1 buildup, we asked whether this effect can be abolished by removing cellular Pfn1. Thus, we performed single or double knockdown of Pfn1 and XPO6 in the
MCF-7 cells (Figure 4B). Consistent with the prior report that
€ ven
XPO6 can export nuclear actin independently of Pfn1 (Stu
et al., 2003), nuclear YFP-actin accumulated upon XPO6 knockdown in Pfn1-silenced cells (Figure S5E). However, unlike in the
control cells, XPO6 knockdown in the Pfn1-silenced MCF-7 cells
caused no growth inhibition (Figures 4B and S5F), suggesting
that nuclear Pfn1 buildup underlies the anticancer effect of
XPO6 loss.
To confirm this finding, we next exploited the Pfn1-null chondrocytes derived from the cartilage-specific Pfn1 KO mice
(Böttcher et al., 2009). Though displaying various abnormalities,

Figure 1. XPO6 upregulation occurs in cancer and associates with poor patient survival
(A) Pan-cancer XPO6 mRNA levels in the TCGA cohorts. Whiskers represent min-max. Mann-Whitney U non-parametric test was used to compare between
normal and tumor samples for each cancer type. RSEM, RNA-seq by expectation maximization.
(B) XPO6 mRNA levels of 112 breast tumors in the TCGA dataset with adjacent normal tissues. p value was based on Wilcoxon Signed Rank non-parametric test.
(C) qRT-PCR of XPO6 mRNA levels in breast epithelial cell lines. One-way ANOVA and Dunnett’s multiple comparisons tests were used to compare between
MCF-10A and breast cancer cell lines. Data are mean ± SEM. **p < 0.01; ***p < 0.001; ****p < 0.0001.
(D) Western blot of XPO6 in untransformed and transformed breast epithelial cell lines, with different cytoplasmic and nuclear proteins as controls.
(E) Univariate Kaplan-Meier analysis of the association between XPO6 mRNA levels and the overall survival (OS) of TCGA patients with bladder, renal clear cell,
hepatocellular, and breast carcinomas.
(F) Univariate Kaplan-Meier analysis of the association between XPO6 mRNA levels and the OS of stage II breast cancer patients within the TCGA cohort.
(G) Univariate Kaplan-Meier analysis of the association between XPO6 protein levels and the OS of a cohort of 65 breast cancer patients.
p values for (E)–(G) were based on log-rank tests. See also Figures S1 and S2 and Tables S1A–S1C.
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Figure 2. XPO6 is required for breast cancer
cell growth in vitro
(A) Human breast epithelial cell lines were infected
with a small hairpin targeting luciferase (shLUC)
and two different XPO6 shRNAs.
(B) Relative growth effects of XPO6 knockdown by
dividing normalized Alamar blue values (day 9/1) of
shXPO6 versus shLUC cells. Data are mean ±
SEM of a representative experiment (sextuples per
condition). p values were based on one-way
ANOVA and Dunnett’s multiple comparison tests.
(C) Colony formation assay using cells in (A).
(D) Colony formation assay using MCF-10A cells
infected with XPO6 or luciferase. Colony areas
were expressed as percentages. Data are mean ±
SEM of a representative experiment (triplicates
per condition).
(E) MCF-7 cells expressing WT or RNAi-Res XPO6
were infected with shLUC or shXPO6 #3 and subjected to Western blot analysis. Lanes for the E2F1
blot were cropped and rearranged from the same
blot (indicated by the black line). Relative growth
effects of XPO6 knockdown were calculated by
normalizing colony areas of shXPO6 versus shLUC
cells. Data are mean ± SD of one representative
experiment (triplicates per condition).
(F) MCF-7 cells infected with shLUC or shXPO6 #3
were labeled with BrdU and stained for BrdU or with
propidium iodide (PI). Fifteen random fields were
quantified. Percent BrdU positivity of cells in all
images is shown. Data are mean ± SEM. Scale
bars, 40 mm.
(G) MCF-7 cells from (F) were synchronized by
double thymidine block, released for different
hours, and analyzed for DNA contents.
p values for (D)–(F) were based on unpaired t test.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. All
results were confirmed by three independent experiments. See also Figures S3 and S4.

these cells are viable in part due to the compensation from Pfn2
(Böttcher et al., 2009). We previously showed that the morphological and growth defects of Pfn1 null chondrocytes can be
rescued by Pfn1 that is untagged or fused to a NES but not a nuclear localization sequence (NLS) (Diamond et al., 2015). XPO6
knockdown caused no growth inhibition of Pfn1-null chondrocytes infected with an empty vector or YFP (Figures 4C and
4D). Re-expressing untagged or YFP-tagged Pfn1 restored
growth inhibition by XPO6 knockdown (Figures 4C, 4D, S5G,
and S5H). However, YFP-Pfn1 tagged with an NES, which converts it to a cargo of XPO1 and prevents its nuclear buildup by
XPO6 loss, could not restore the shXPO6-induced growth inhibition (Figures 4D and S5H). Together, these data suggest that nuclear Pfn1 accumulation is the underlying cause for cell growth
inhibition by XPO6 loss. Notably, the growth inhibition caused
by XPO6 knockdown in the mouse chondrocytes differs from
its lack of effect in the human mammary epithelial MCF-10A
cells. This suggests that non-cancer cells, depending on tissue

origin and cellular contexts, may have
different sensitivity to nuclear Pfn1
accumulation.
Unlike the near-uniform XPO6 upregulation in cancer, Pfn1
shows mixed patterns of dysregulation. Out of the 12 TCGA
cancer types in which Pfn1 mRNA is significantly altered, seven
show upregulation and five show downregulation (Figure S6A;
Table S1D). In TCGA breast tumors, Pfn1 mRNA is significantly
upregulated (Figures S6A and S6B), and its protein level is
markedly higher in the same panel of breast cancer cell lines
overexpressing XPO6 (Figure S6C). However, in the CPTAC dataset, Pfn1 protein is significantly downregulated in the breast
tumors (Figure S6D). Mixed associations between Pfn1 levels
and breast cancer survival were also observed. While high
Pfn1 mRNA levels correlate with better survival of stage II (Figure S6E) and lymph-node-negative (Figure S6F; p = 0.12, statistically insignificant) TCGA patients, an opposite trend was
observed in the combined GEO and EGA datasets where high
Pfn1 mRNA levels correlate with worse survival of lymphnode-negative patients (Figure S6G). Further testing of an individual GEO dataset (GSE21653, showing negative correlation
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Figure 3. XPO6 loss inhibits breast cancer
growth in vivo
(A) MCF-7 cells expressing XPO6(WT) or
XPO6(RNAi-Res) were infected with shLUC or
shXPO6 #3 and inoculated in female nude mice
(n = 6). Caliper measurement of tumors began at
day 15. Two-way ANOVA and Sidak’s multiple
comparison tests were used to compare tumor
volumes between shLUC and shXPO6 groups.
(B) Endpoint tumor weights. p values were based
on one-way ANOVA and Tukey’s multiple comparison tests.
(C and D) Three randomly selected tumors per
group were immunostained for p-Rb(Ser795) (C)
and Ki67 (D). Positive tumor cells from random
fields of each image were normalized against total
tumor cells stained by hematoxylin. Each dot
represents 300–450 tumor cells. Scale bars,
100 mm.
p values were based on one-way ANOVA and
Tukey’s multiple comparison tests. All data are
mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001.

between XPO6 and survival of lymph-node-positive patients in
Figure S2F) revealed positive versus negative associations between Pfn1 mRNA levels and the survival of lymph-node-negative and lymph-node-positive patients, respectively (Figure S6H). Nevertheless, no association between Pfn1 protein
levels and survival was observed in the same proteomic dataset (Figure S6I) that showed significant association between
high XPO6 and worse survival (Figure 1G). These variable results regarding Pfn1 expression and outcome associations, in
clear contrast to XPO6, are consistent with the pleiotropic functions of Pfn1 and suggest that its tumor-supportive versus
inhibitory activities are balanced in cancer cells stochastically.
Therefore, total Pfn1 levels do not accurately reflect its anticancer activities.
Nuclear Pfn1 interacts with the SEC
In addition to nuclear entry, our prior study suggested that
Pfn1’s ability to bind PLP motifs is also important for its anti-
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cancer activity (Diamond et al., 2015).
Although PLPs mediate the direct interaction of Pfn1 with a multitude of cytoplasmic proteins, few nuclear-binding
partners of Pfn1 are known. Thus, we
performed immunoprecipitation (IP) of
NLS-tagged YFP-Pfn1 from MDA-MB231 nuclear extracts followed by mass
spectrometry (MS) analysis to identify
associated proteins. We used YFP as a
non-specific binding control and a
mutant NLS-Pfn1(S137D) unable to
bind PLPs (Diamond et al., 2015) to
exclude PLP-independent interactions
(Figure 5A). Based on a 1% peptide false
discovery rate and a relative protein
expression ratio of >1.5 in the NLSPfn1(WT) versus YFP and NLS-Pfn1 S137D, we identified 37
proteins interacting with NLS-Pfn1(WT) in a PLP-dependent
fashion (Table S2).
Three proteins contain the canonical Pfn1-interacting PLP motifs. They are BOD1L1, SFPQ, and MLLT1/ENL. BOD1L1 is a
limitedly characterized protein with a role in DNA replication
fork stability (Higgs et al., 2015). SFPQ is a multi-functional protein involved in pre-mRNA splicing and context-dependent transcriptional regulation (Fox and Lamond, 2010). ENL is an acetyllysine-binding transcriptional activator functioning primarily
within the multi-component SEC. The SEC is a positive regulator
of transcriptional elongation by phosphorylating Ser2 of the Rpb1
subunit of RNA polymerase II (RNA Pol II) via the associated pTEFb dimeric complex comprising Cdk9 and cyclin T1 or T2.
This releases RNA Pol II from the ‘‘paused’’ state at the promoter
proximal regions of many active genes and leads to their productive elongation (Luo et al., 2012b). Notably, in addition to ENL, we
detected three SEC components by MS including AFF4, ELL,
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Figure 4. Nuclear Pfn1 is required for the growth inhibitory effect of XPO6 loss
(A) MCF-7 cells expressing XPO6(WT) or XPO6(RNAi-Res) were infected with shLUC or shXPO6 #3 and subjected to immunofluorescence staining for
endogenous Pfn1 and nuclear staining by DAPI. Representative images and quantitative analysis of nuclear versus cytoplasmic fluorescence intensity are shown.
Over 500 cells per condition were analyzed. Data are mean ± SEM. p values were based on unpaired t tests. Scale bars, 20 mm.
(B) MCF-7 cells were infected individually or simultaneously with shPFN1 (#2) (controlled by shCTRL) and shXPO6 #3 (controlled by shLUC). Relative cell growth
rates were expressed as day 11/day 1 ratios as described in Figure 2B.
(C and D) Pfn1-null mouse chondrocytes were first infected with untagged Pfn1 (controlled by empty vector; C) or YFP-Pfn1 with or without an NES tag (controlled
by YFP; D), followed by further infection with shLUC or shXPO6 #2 (recognizing mouse XPO6). Cells were subjected to western blot (Pfn1 antibody [C] and GFP
antibody [D]) and growth analyses as described in (B).
For (B)–(D), relative growth of shLUC cells in each subgroup was arbitrarily set to 1. Data are mean ± SEM of a representative experiment (sextuplicates per
condition). p values were based on unpaired t tests. **p < 0.01; ****p < 0.0001. Results were confirmed by three independent experiments. See also Figures S5 and
S6 and Table S1D.

and cyclin T1, all of which preferentially bound NLS-Pfn1(WT)
over NLS-Pfn1(S137D) and YFP (Figure 5B).
Focusing on SEC, we confirmed the MS data by co-IP
and western blot using MCF-7 cells. In addition to ENL and
Cyclin T1, we detected interactions of Cdk9 and Rbp1 with
NLS-Pfn1(WT) but not NLS-Pfn1(S137D) or YFP (Figure 5C).
We could not validate AFF4 interaction due to the performance
issue of the antibody. To confirm the interaction of the SEC
with endogenous Pfn1, we performed reciprocal IPs of ENL
and cyclin T1. We detected specific co-precipitation of endoge-

nous Pfn1 by ENL antibody and, to a much lesser extent, cyclin
T1 antibody (Figure 5D). While similar amounts of Cdk9 were coprecipitated by ENL and cyclin T1, less ENL was pulled down
indirectly by cyclin T1 than directly by ENL antibody. This is
consistent with the fact that p-TEFb (cyclin T1/Cdk9) associates
with different partners besides SEC (e.g., BET domain proteins)
(Luo et al., 2012a), and further implicates that the Pfn1/SEC interaction is mediated directly by the PLP motif in ENL. Consistent
with this, cyclin T1/Pfn1 interaction was significantly reduced
by ENL knockdown (Figure 5E). In addition, we performed size-
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Figure 5. Nuclear Pfn1 interacts with the SEC
(A) IP of YFP or YFP-NLS-Pfn1(WT or S137D) from nuclear extracts of MDA-MB-231 stable cells by a GFP antibody, followed by silver staining.
(B) Eluates from (A) were analyzed by liquid chromatography-MS. Proteins specifically bound to NLS-Pfn1(WT) were identified using label-free quantification
(LFQ) intensity and a threshold of >1.5-fold-higher intensity over those bound to YFP and NLS-Pfn1(S137D). LFQ intensities of detectable SEC components are
shown.
(C) Confirmation of the interaction between NLS-Pfn1(WT) and SEC by anti-GFP co-IP as in (B) using nuclear extracts of stable MCF-7 cells, followed by western
blot.
(D) Interaction between the SEC and endogenous Pfn1 in MCF-7 cells. ENL and cyclin T1 were pulled down followed by western blot.
(E) Cyclin T1 pulldown from shLUC- versus shENL-infected MCF-7 cells, followed by western blot for endogenous Pfn1 and other proteins. In total, 50-fold-less
input was used for the Pfn1 blot given the small fraction of nuclear Pfn1 (most in the cytoplasm) interacting with the SEC.
(F) Size-exclusion chromatography and western blot analyses of nuclear extracts of MDA-MB-231 cells for endogenous Pfn1 and SEC components.
Results in (C)–(F) were confirmed by three independent experiments. Lanes in (A), (D), and (E) were cropped and rearranged from the same blots for clarity of
presentation (indicated by the black lines). See also Table S2.

exclusion chromatography using MDA-MB-231 nuclear extracts. We detected partially overlapping distribution of p-TEFb
and ENL, consistent with a prior report (Luo et al., 2012a). Importantly, endogenous Pfn1 showed a narrow size distribution that
overlaps with both ENL and p-TEFb (Figure 5F). Collectively,
our data revealed a previously unknown interaction between nuclear Pfn1 and the SEC via the direct binding of Pfn1 to the PLP
motif within ENL.
Nuclear Pfn1 inhibits SEC-dependent transcription of cMYC
The role of the SEC in transcriptional checkpoint regulation is
well known for developmental and stimulus-induced genes. In
the context of cancer, the best-characterized SEC target gene
is MYC (Luo et al., 2012b). To determine if the interaction of nuclear Pfn1 with the SEC is functionally relevant to its anticancer
activity, we examined the effect of NLS- or NES-tagged YFPPfn1 on MYC expression by qRT-PCR (Figures 6A, 6B, S7A,
and S7B). NLS-Pfn1(WT), but not NES-Pfn1(WT), significantly
decreased MYC mRNA levels in both breast cancer cell lines
and untransformed MCF-10A cells. The PLP-binding defective
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NLS-Pfn1(S137D) did not inhibit MYC expression, instead
slightly increasing its levels (Figures 6B and S7B). Similarly,
MYC mRNA levels were decreased by XPO6 knockdown, and
the effect was rescuable by XPO6(RNAi-Res) (Figures 6C and
S7C). Analyzing tumors from the MCF-7 xenograft experiment
(Figure 3) showed that MYC mRNA downregulation by XPO6
knockdown also occurred in vivo (Figure 6D).
To causally link Pfn1 to MYC reduction by XPO6 knockdown,
we used the Pfn1-null mouse chondrocytes described in Figures
4C and 4D (Böttcher et al., 2009). Consistent with nuclear Pfn1
mediating the effect of XPO6 knockdown, we observed no inhibition of MYC expression by XPO6 knockdown in the absence of
Pfn1. However, MYC was inhibited when Pfn1 was re-expressed
(Figure 6E). Conversely, Pfn1 knockdown significantly increased
MYC mRNA levels (Figure 6F).
We next sought for clinical evidence in the TCGA datasets for
transcriptional inhibition of MYC by nuclear Pfn1. We found a
positive correlation between MYC and XPO6 mRNA levels
(Spearman correlation coefficient r > 0) in 25 out of 32 cancer
types, with 15 (including breast cancer) being statistically significant (Figure 6G; Table S3). Among the 15 cancer types, r values
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Figure 6. Nuclear Pfn1 inhibits SEC function
(A) Western blot of NLS- or NES-tagged YFP-Pfn1 relative to endogenous Pfn1 by GFP or Pfn1 antibodies. S137D, residing in the epitope of the Pfn1 antibody,
abolishes the detection.
(B) qRT-PCR of MYC in MCF-7 cells in (A). p values were based on unpaired t test relative to YFP control.
(C) qRT-PCR of XPO6 and MYC in MCF-7 cells expressing XPO6(WT) or XPO6(RNAi-Res) and infected with shLUC or shXPO6 (#3). p values were based on
unpaired t test by comparing shLUC versus shXPO6 #3.
(D) qRT-PCR of MYC in XPO6 KD/rescue MCF-7 xenograft samples (10 tumors/group, 2 technical replicates/tumor) from Figure 3. p values were based on
unpaired t test.
(E) qRT-PCR of MYC in Pfn1-null chondrocytes infected first with vector or Pfn1 and subsequently with shLUC or shXPO6 #2 (recognizing mouse XPO6). p values
were based on unpaired t test.
(F) qRT-PCR of MYC and Pfn1 in MCF-7 cells expressing Pfn1(WT) or Pfn1(RNAi-Res) and infected with scrambled shCTRL or shPFN1 #1 or #2. p values were
based on unpaired t test by comparing shCTRL versus shPFN1.
(G) Correlations of MYC mRNA levels with XPO6, BRD4, and NCL in different TCGA datasets. The y axis represents Spearman’s correlation coefficients (r).
Fifteen cancer types in which statistically significant positive correlations between XPO6 and MYC expression are shown (r > 0; FDR q values < 0.05).
(H) ChIP using antibodies for ENL, cyclin T1, Cdk9, p-Rpb1(Ser2), and H3K36me3 from MCF-7 cells expressing YFP or YFP-NLS-Pfn1(WT or S137D) followed by
MYC qPCR. p values were based on unpaired t test.
(I) ChIP using antibodies for ENL, p-Rpb1(Ser2), and H3K36me3 from MCF-7 cells infected with shLUC or shXPO6 #3 followed by MYC qPCR.
p values were based on unpaired t test. All data (except A and G) represent mean ± SEM of representative experiments, which were confirmed at least three times.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S7 and Table S3.
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Figure 7. XPO6 loss triggers anticancer transcriptomic effects and sensitization to BET inhibitor JQ1
(A) RNA-seq using shLUC- or shXPO6-#3-infected MCF-7 cells expressing XPO6(WT) or XPO6(RNAi-Res). GSEA evaluating changes in the 50 hallmark gene sets
induced by XPO6 knockdown. Shown are MYC targets V1 and V2 gene sets.
(B and C) qRT-PCR validation of DE genes induced by XPO6 knockdown specifically in MCF-7 cells expressing XPO6(WT) but not XPO6(RNAi-Res). (B) XPO6 and
MYC target genes NCL (activated) and HMOX1 (repressed) were analyzed. (C) Various known SEC target genes were analyzed. p values were based on unpaired t
test by comparing shLUC versus shXPO6 for each gene.
(D) Representative gene sets significantly enriched by XPO6 knockdown in MCF-7 cells expressing XPO6(WT) but not XPO6(RNAi-Res). Analysis was performed
using R/GAGE against GO molecular functions and multiple curated MSigDB databases (hallmark, KEGG, Reactome, Chemical and Genetic Perturbation) and
graphed by R/ggplot2.

(legend continued on next page)
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for XPO6 and MYC range from 0.1 to 0.46. The r for breast cancer is 0.15, ranking XPO6 within the top 16% of all genes positively correlated with MYC (Figure S7D). As a control, we detected positive correlations between MYC and BRD4 (positive
regulator of MYC) in 28 out of 32 tumor types, with 15 being statistically significant (Figure 6G). Correlation coefficients for MYC
and BRD4 range from 0.1 to 0.41, comparable to those for MYC
and XPO6 (Table S3). As an additional control, we detected positive correlations between MYC and its target gene NCL in all 32
tumor types, with 30 being statistically significant (r, 0.04–0.67)
(Figure 6G; Table S3).
Next, we performed chromatin IP (ChIP) using MCF-7 cells to
determine whether the inhibitory effect of nuclear Pfn1 on MYC
transcription was due to decreased chromatin occupancy of
SEC. Using antibodies for ENL, Cdk9, and cyclin T1 and MYCspecific primers (He et al., 2011), we detected significant inhibition of chromatin occupancy of the SEC by both NLS-Pfn1(WT)
and XPO6 knockdown (Figures 6H and 6I). Consistent with the
importance of PLP binding in Pfn1/SEC interaction, NLSPfn1(S137D) failed to inhibit SEC chromatin occupancy. Instead,
it increased SEC occupancy at the MYC gene locus, mirroring its
effect on MYC mRNA levels and indicating a dominant-negative
effect. Since the SEC promotes gene transcription by phosphorylating Ser2 of Rpb1, we performed ChIP for p-Rpb1(Ser2).
Reduced p-Rpb1(Ser2) levels were observed at the MYC locus
by NLS-Pfn1(WT) expression and XPO6 knockdown (Figures
6H and 6I). The inhibitory effect of nuclear Pfn1 on MYC occupancy of the SEC and p-Rpb1(Ser2) was similarly induced by untagged Pfn1 in a PLP-binding dependent fashion (Figure S7E).
Conversely, Pfn1 knockdown increased MYC occupancy of the
SEC and p-Rpb1(Ser2) (Figure S7F). Further, H3K36me3, a positive transcriptional marker depending on transcriptional elongation by p-Rpb1(Ser2) (Edmunds et al., 2008), was significantly
decreased at the MYC locus by NLS-Pfn1(WT) and XPO6 knockdown (Figures 6H and 6I). These data suggest that nuclear Pfn1,
increased by XPO6 loss, inhibits the transcription of MYC by
blocking chromatin recruitment of SEC and the consequent
Ser2 phosphorylation of RNA Pol II necessary for transcription
elongation.
XPO6 loss triggers anticancer transcriptomic changes
and sensitization to BET inhibition
To understand the broader transcriptional impact of nuclear
Pfn1, we performed RNA-seq using XPO6 knockdown/rescue
MCF-7 cells. We first performed gene set enrichment analysis
(GSEA) using the differential expression values (fold change of
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shXPO6 versus shLUC) of all detected genes in XPO6(WT) or
XPO6(RNAi-Res) cells. Using the well-annotated hallmark gene
sets in the Molecular Signatures Database (MSigDB), we
observed significant enrichment in nine gene sets (Figures 7A,
S8A, and S9; Table S4A). Notably, all nine gene sets are negatively enriched by XPO6 knockdown, reflecting gene downregulation, and insignificant in the XPO6(RNAi-Res) cells (Figures 7A,
S8A, and S9; Table S4A), confirming that the effects are due to
XPO6 loss. Among them, the first and third highest-ranked
gene sets by normalized enrichment score are MYC targets V1
and V2. We further confirmed this by examining the transcript
levels of NCL, a known MYC-activated gene, and HMOX1, a
known MYC-repressed gene, which were inhibited and promoted by XPO6 knockdown, respectively (Figure 7B). In addition
to MYC targets, reduced expression of multiple known SEC
target genes (Lin et al., 2011; Luo et al., 2012a) as a result of
XPO6 knockdown in XPO6(WT) but not XPO6(RNAi-Res) cells
was detected by RNA-seq and validated by qRT-PCR (Figure 7C). The additional hallmark gene sets in which shXPO6induced differentially expressed (DE) genes were negatively enriched include E2F targets, epithelial mesenchymal transition,
unfolded protein response, MTORC1 signaling, oxidative phosphorylation, reactive oxygen species pathways, and adipogenesis, all of which were rescued by XPO6(RNAi-Res) (Figures S8A
and S9; Table S4A). This indicates that XPO6 loss inhibits a multitude of cancer-driving processes related to proliferation, metastasis, and metabolism.
To investigate this further, we performed pathway analyses for
statistically significant shXPO6-induced DE genes (adjusted p
value < 0.05). Using Gene Ontology (GO) and several MSigDB
gene sets, we detected, specifically in the XPO6(WT) cells, statistically significant downregulation of five additional MYC target
gene sets besides the two hallmark MYC targets V1 and V2 (Figure 7D). Consistent with the GSEA results, we also detected significant downregulation of multiple gene sets related to proliferation, metastasis, transcription, and translation (Figure 7D; Table
S4B). In addition, we detected significant downregulation of multiple stem-cell-related gene sets and EZH2-stimulated genes,
accompanied by the upregulation of EZH2-repressed genes
bearing the H3K27me3 mark (Figure S8B). Thus, XPO6 loss triggers transcriptomic changes indicative of the suppression of
multiple phenotypic aspects of cancer.
The SEC and BET families of bromodomain-containing proteins have similar functions in promoting oncogenic transcription
by independently binding p-TEFb and phosphorylating Ser2 of
RNA Pol II. It was recently reported that SEC inhibition via ENL

(E) MDA-MB-231 cells infected with control or sgXPO6 viruses were treated with DMSO or JQ1 in colony formation assays for 10 days. p values were based on
one-way ANOVA and Dunnett’s multiple comparisons by comparing control and sgXPO6 cells at different JQ1 concentrations. Data in (B), (C), and (E) are mean ±
SEM of representative experiments (triplicates per condition) and were confirmed three times.
(F) MDA-MB-231 cells from (E) were orthotopically injected into female nude mice and treated with vehicle or JQ1 for 3 weeks. Mice in the sgXPO6 #1 and #3
groups were combined for analysis. Arrows indicate treatment start dates. p values were based on two-way ANOVA and Sidak’s multiple comparison tests to
compare vehicle versus JQ1 groups.
(G) Relative growth rates of individual tumors during the dosing period were first calculated by dividing tumor volumes at various time points by day 1. The
calculated tumor growth rates in the JQ1 groups of control or sgXPO6 mice were subsequently divided by the averaged growth rates of the corresponding vehicle
groups, giving rise to the relative JQ effect (y axis).
p values were based on two-way ANOVA and Sidak’s multiple comparison tests. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figures S8–S10 and
Table S4.
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deletion sensitizes leukemia cells to the BET inhibitor JQ1 (Wan
et al., 2017). Since nuclear Pfn1 inhibits SEC function, we asked
whether it could sensitize cancer cells to JQ1. Indeed, XPO6
knockdown (Figure S10A) and KO (Cas9n, Figure S10B; Cas9,
Figure 7E) both rendered the triple-negative MDA-MB-231 cells,
known to depend on Brd4 function, more sensitive to JQ1
in vitro. To confirm this in vivo, we orthotopically injected MDAMB-231 cells infected with control or two different sgXPO6 viruses in female nude mice. When the average tumor volumes
in each group reached 70 mm3, we randomly divided and
treated them daily with vehicle or JQ1 for 3 weeks. Control cells
formed tumors significantly faster (by 2 weeks) at a higher frequency (90% versus 50% of injection sites) than the XPO6 KO
cells (Figure 7F). Because of the low tumor take rate of XPO6
KO cells, the two sgXPO6 groups were combined for data analysis to increase statistical power. Statistically significant tumor
inhibition by JQ1 was observed at multiple time points posttreatment in the sgXPO6 group but not the control group (Figure 7F), and the relative difference in tumor volumes between
JQ1 and vehicle-treated mice was significantly larger in the
sgXPO6 group than the control group (Figure 7G). Notably,
XPO6 protein levels remained low in the resected tumors of the
sgXPO6 groups but visibly higher than the levels prior to mouse
inoculation (Figures S10C and S10D). This indicates a selection
pressure during in vivo expansion to restore XPO6 expression
or the amplification of a small fraction of tumor cells with inefficient XPO6 KO. Regardless, our data demonstrate that in addition to being a therapeutic target on its own, XPO6 may be inhibited to enhance the anticancer efficacy of BET inhibitors.
DISCUSSION
An emerging paradigm of non-oncogene addiction in cancer is
altered nucleocytoplasmic protein trafficking caused by aberrant
expression of nuclear transporters. Here, we focused on the
highly selective nuclear exporter XPO6, whose only known cargo
€ven et al., 2003). Despite the
is the dimeric actin/Pfn complex (Stu
largely unexplored role of XPO6 in cancer, we were intrigued by
the long-standing paradox regarding the opposing cellular functions of its cargo Pfn1. Although the essentiality of Pfn1 explains
the extreme rarity of its loss-of-function mutations in cancer,
both its clinical relevance and anticancer mechanism remain
poorly defined. Adding to the complexity are the inconsistent
patterns of Pfn1 expression changes in cancer. Our earlier report
indicated that cell nucleus might be the spatial origin of Pfn1’s
anticancer function (Diamond et al., 2015). Work in this paper
supports this theory and suggests that Pfn1 is deregulated in
cancer primarily on the protein level through nuclear exclusion
caused by XPO6 upregulation. This model not only reconciles
the paradoxical Pfn1 functions that co-exist in normal cells, but
also explains how cancer cells can specifically inhibit the anticancer activity of Pfn1 without compromising its essential cytoplasmic function.
By analyzing publicly available human cancer data, we detected widespread upregulation of XPO6 mRNA within
numerous tumor types. For breast cancer, this does not depend
on stage or subtype, indicating that XPO6 upregulation may be
an early and prevalent cancer-associated event. High levels of

12 Cell Reports 34, 108749, February 16, 2021

Article
XPO6 mRNA and protein correlate with poor breast cancer survival. Interestingly, our analyses suggested that XPO6 level is
preferentially associated with the survival of lymph-node-positive breast cancer patients. While this implies a greater impact
of XPO6 on invasive breast cancer, we did not observe a correlation between XPO6 and breast cancer progression using the
TCGA dataset. Nonetheless, this possibility may be further
tested in the future using independent datasets.
In support of patient data, we showed that XPO6 loss caused
growth inhibition of multiple breast cancer cell lines, regardless
of subtype, and two sarcoma cell lines in vitro. This was
confirmed in vivo using orthotopically implanted MCF-7 cells.
In our experimental systems, cell-cycle inhibition appears to be
a major factor underlying the anticancer effect of XPO6 loss.
This supports prior findings that Pfn1, the cargo of XPO6, causes
cell-cycle arrest in breast cancer cells (Diamond et al., 2015; Zou
et al., 2010). Intriguingly, XPO6 loss did not trigger detectable
growth inhibition of the untransformed mammary epithelial
MCF10A cells. However, the growth inhibition by XPO6 knockdown in the mouse chondrocytes indicates that tolerability of
XPO6 inhibition by healthy cells may depend on their tissue origins and contexts. This will be an important question to address
in future studies.
By discovering the interaction between Pfn1 and the SEC, we
defined a molecular function of nuclear Pfn1 and linked it directly
to cancer. The SEC has been extensively studied for its role in
productive transcriptional elongation (He et al., 2010; Lin et al.,
2010; Sobhian et al., 2010). Its cancer relevance has long been
implicated by the frequent fusion between its different components and the MLL oncogene in childhood leukemia. A recent
study showed that MLLT1 (encoding ENL) mutations are causally linked to Wilms tumors (Perlman et al., 2015). Even in the
absence of genetic aberrations, the SEC is important for cancer
due to its positive regulation of processive transcription of
various pro-cancer genes, most notably MYC (Liang et al.,
2018). ENL was recently identified as an acetyl-lysine-binding
protein, joining the BET family proteins as an epigenetic reader
(Wan et al., 2017). This supports the idea that the SEC and
BET proteins play similar, albeit non-identical, roles in recruiting
p-TEFb to acetylated chromatin regions to drive transcription.
This is consistent with the finding that ENL depletion in leukemia
cells inhibited Cdk9 chromatin recruitment (Wan et al., 2017). As
for negative regulators of p-TEFb, for nearly two decades the
7SK small nuclear ribonucleoprotein (snRNP) complex remains
its only known inhibitor (Nguyen et al., 2001; Yang et al., 2001).
However, it is unknown whether p-TEFb can be inhibited outside
of 7SK snRNP, especially when it is bound with positive regulators. We show that nuclear Pfn1 interacts with the SEC, via direct
binding to the PLP motif in ENL, and reduces SEC chromatin occupancy at the MYC locus. This is associated with decreased
levels of p-Rpb1(Ser2) (indicative of lower p-TEFb activity) at
the MYC gene locus and downregulation of its expression. Interestingly, separate SECs exist containing either ENL or AF9 that
occupy the same region in the scaffold protein AFF4. The
absence of a PLP motif in AF9 may explain why it was not detected as a binding partner of nuclear Pfn1. Thus, we have identified nuclear Pfn1 as a negative regulator of p-TEFb in the
context of ENL-containing SEC.
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Consistent with our hypothesis that the pro-cancer effect of
XPO6 stems from its ability to reduce nuclear Pfn1 level, XPO6
loss causes a similar inhibition of SEC occupancy at the MYC
gene locus and MYC expression. Importantly, both the inhibitory
effects of XPO6 loss on MYC expression and cancer cell growth
are abolished when Pfn1 is absent, suggesting that it is the nuclear accumulation of Pfn1, rather than actin, that underlies these
effects. This is consistent with the positive regulation of general
transcription by nuclear actin (Virtanen and Vartiainen, 2017). In
fact, in Pfn1-null mouse chondrocytes, XPO6 loss causes a
small, but reproducible, increase in MYC expression and cell
growth. Since actin can be exported by XPO6, albeit less efficiently, in the absence of Pfn1, this functionally separates nuclear Pfn1 and actin with regard to their roles in gene regulation.
The inhibitory effect of XPO6 loss on the SEC was further
confirmed by genome-wide transcriptomic analysis, which
showed significant downregulation of multiple MYC target
gene sets and known SEC target genes. Since the SEC both promotes MYC expression as a target gene (Luo et al., 2012a) and
functionally collaborates with MYC as a transcription factor
(Liang et al., 2018), the mechanism behind the inhibition of
MYC target genes by nuclear Pfn1 could be 2-fold. The significant downregulation of genes involved in proliferation (e.g.,
E2F targets) and metastasis (e.g., EMT) by XPO6 loss is consistent with the known anti-proliferative and anti-metastatic effects
of Pfn1 in different tumor models and suggests that these effects
originate, at least partially, from its nuclear function as an inhibitor of SEC-dependent transcription. It was intriguing to observe
the significant downregulation of additional gene sets, as a result
of XPO6 loss, that are functionally associated with diverse
cellular processes including protein translation, oxidative phosphorylation, and adipogenesis as well as those associated with
reactive oxygen species pathways and stem cell signatures, all
of which have been positively linked to MYC activation (Meyer
and Penn, 2008). Consistent with the role of the SEC as a transcriptional activator, nearly all the significantly enriched gene
sets and biological pathways represent downregulated genes
due to XPO6 loss. The only notable exception was an upregulation of two H3K27me3 gene sets representing repressed target
genes of the oncogenic histone methyltransferase EZH2, which
coincide with a downregulation of its activated target genes. It
was previously shown that MYC stimulates EZH2 expression
both transcriptionally as a target gene and post-transcriptionally
by repressing its negative regulator miR-26 (Sander et al., 2008).
Thus, the effect of XPO6 loss on EZH2 function may be similarly,
and at least partially, caused by MYC repression due to SEC
inhibition.
The diverse transcriptional effects and robust antitumor effects
triggered by XPO6 loss provide orthogonal validation of recent
findings that targeting the SEC, either by ENL deletion (Erb
et al., 2017; Wan et al., 2017) or by disrupting AFF4/CycT1 interaction (Liang et al., 2018), achieved significant anticancer effects.
Among various therapeutic implications, the parallel functions of
ENL (in the context of the SEC) and BET proteins as acetyllysine-specific epigenetic readers motivated us to test the influence of XPO6 loss on the anticancer effects of JQ1. Consistent
with a recent report that ENL depletion sensitizes leukemia cells
to JQ1 (Wan et al., 2017), we observed increased growth inhibition

by JQ1 of the triple-negative breast cancer cell line MDA-MB-231
with XPO6 loss. Given the intensive efforts to find synthetic lethal
partners of BET proteins to more effectively treat cancer (Shu
et al., 2016), our data provide important proof-of-concept that
XPO6 may be a potentially useful target in this regard.
In summary, we discovered that XPO6 upregulation is a previously unrecognized cancer driver event. By finding that nuclear
Pfn1, the cargo of XPO6, is a physical binding partner and functional inhibitor of the SEC, we defined a moonlighting function of
nuclear Pfn1 in transcriptional repression that is mechanistically
linked to its poorly understood anticancer function. Our work
highlights the importance of subcellular localization in protein
function and the oncogenic effects of protein spatial deregulation that may arise due to aberrant expression of nucleocytoplasmic transporters. Future studies to expand our knowledge
of spatially dynamic, multi-functional proteins such as Pfn1 are
warranted and will likely unveil hidden biology, as well as therapeutic opportunities to treat cancer.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jieya
Shao (shao.j@wustl.edu)
Materials availability
Reagents generated in this study will be made available on request with a completed Materials Transfer Agreement.
Data and code availability
RNA-seq data generated in this study are available at the GEO data depository under accession number GSE144372. No unique
code was generated.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
All cell lines except for mouse chondrocytes were purchased from ATCC and authenticated and tested for mycoplasma. MCF-10A
cells were grown in DMEM/F12 plus 5% or 10% horse serum and supplements (50 mg/mL gentamycin, 20 ng/mL EGF, 0.5 mg/mL
hydrocortisone, 100 ng/mL cholera toxin, and 10 mg/mL insulin). HuMEC cells were cultured using the MammaryLife Medium complete kit (Lifeline Cell Technology, CA, cat #LL-0061). MCF-7 and T47D cells were grown in RPMI 1640 plus 5% or 10% fetal bovine
serum (FBS) and supplements (50 mg/mL gentamycin, 1mM sodium pyruvate, 10 mM HEPES and glucose to 4.5 g/L). MDA-MB-231,
BT-549, CAMA-1, HCC70, HEK293T, and mouse chondrocytes were grown in high glucose DMEM plus 5% or 10% fetal bovine
serum and 50 mg/mL gentamicin. SK-UT-1 and SK-LM-1 were grown in MEM plus 10% fetal bovine serum and 50 mg/mL gentamicin.
Animal experiments
All animal experiments were performed in accordance with the guidelines recommended by the National Institutes of Health. 4-week
old female NU/NU nude mice were purchased from Charles River and kept for one week under standard institutional care. For ERpositive MCF-7 cells, estrogen pellets (17b estradiol, 0.75 mg/pellet, 90 days release; Innovative Research of America, Sarasota, FL)
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were implanted subcutaneously a day before tumor cell implantation. MCF-7 cells stably expressing XPO6(WT) and XPO6 (RNAiRes) and infected with shLUC or shXPO6#3, were trypsinized, washed with and re-suspended in Hank’s balanced salt solution
(HBSS), and mixed at a 1:1 ratio with Matrigel (356237, BD Biosciences). 5 3 106 (in 75 ml) cells were injected bilaterally into the
4th mammary glands of each mouse (6 mice/group). For ER- MDA-MB-231 cells stably infected with lentiCRISPRv2.0 lacking (control) or containing sgXPO6 #1 or #3, 1.7 3 106 in 75 ml were injected bilaterally into the 4th mammary fad pads of female nude mice
without estrogen pellets (10 mice per group). Tumor volumes were measured bi-weekly by Caliper. Tumor volumes were calculated
using the formula: tumor volume [mm3] = 1/2 x (tumor length) x (tumor width)2 . For MCF-7 cells, the experiment was terminated at
11 weeks post injection when the largest tumors reached around 1.5cm in diameter. For MDA-MB-231 cells, mice in each group were
randomly divided into vehicle and JQ1 treatment groups (3-5 mice per group depending on the numbers of tumor-bearing mice) when
the average tumor volume reached approximately 70mm3. JQ1 (S7110, Selleckchem) was freshly prepared each day by diluting 10x
stock solution (0.5 mg/6 ml, 83.3mg/ml, in DMSO) into 1x working solution (0.05 mg/6 ml) using vehicle (10% hydroxypropyl beta
cyclodextrin in 0.9% sodium chloride). Mice received intraperitoneal injection of equal volume of vehicle or JQ1 at a daily dose of
50mg/kg for three weeks, during which tumors were measured semiweekly. Mice were euthanized and tumors were resected,
weighed, and saved for further analyses.
METHOD DETAILS
Antibodies
Primary antibodies used for western blot are as follows: rabbit anti-XPO6 (Thermo Fisher, #PA5-31813), mouse anti-RPb1(CTD) (Cell
Signaling, #2629), rabbit anti-Cdk9 (Cell Signaling, #2316), rabbit anti-cyclin T1 (Cell Signaling, #81464), rabbit anti-GFP (Cell
Signaling, #2956), rabbit anti-Histone H3 (Cell signaling, #4499), rabbit anti-Pfn1 (Cell signaling, #3237; Abcam, ab124904, Sigma,
P7624), rat anti-GFP (Biolegend, 338002), rabbit anti-ENL (Bethyl lab, A302-268A), mouse anti-GAPDH (Santa cruz, sc-47724), rabbit
anti-GAPDH (Cell Signaling, # 5174), mouse anti-a-tubulin (Santa Cruz, sc-5286). mouse anti-b-actin (Santa Cruz, sc-47778), rabbit
anti-p-Rb(Ser795) (Cell Signaling, #9301), mouse anti-E2F-1 (Santa Cruz, sc-56661), rabbit anti-Cyclin D1 (Cell Signaling, #2978) antibodies. Primary antibodies for ChIP include rabbit anti- p-Rpb1(Ser2) (CTD) (Cell Signaling, #13499), rabbit anti-Cdk9 (Cell
Signaling, #2316), rabbit anti-cyclin T1 (Cell Signaling, #81464), rabbit anti-ENL (Bethyl lab, A302-268A), rabbit anti-H3K36me3
(Cell Signaling, #4909) antibodies. Primary antibodies used for immunoprecipitation are as follows: mouse anti-GFP (DSHB,
#12E6), GFP-Trap agarose (Chromotek, Cat # gta-20), rabbit anti-ENL (Bethyl lab, A302-267A), mouse anti-cyclin T1 (Santa Cruz,
sc-271575), control IgG (Santa Cruz, sc-2027 and sc-2025). Mouse anti-BrdU antibody for immunofluorescence staining (B2531)
was purchased from Sigma. Primary antibodies for immunofluorescence staining include rabbit anti-Pfn1 (Abcam, ab124904). Antibodies for immunohistochemistry include rabbit anti-Ki67 (Santa Cruz, sc-15402), rabbit anti-p-Rb(Ser795) (Cell Signaling, #9301)
antibodies. Secondary antibodies for western blots are horseradish peroxidase-conjugated anti-rabbit (Cell Signaling, #7074),
anti-mouse (Cell Signaling, #7076), and anti-rat (Cell Signaling, #7077) antibodies. Secondary antibodies for immunofluorescence
are Alexa Fluor 488-conjugated goat anti-mouse or rabbit IgG (H+L) (Invitrogen, A-11029 and A-11008). Secondary antibodies for
immunohistochemistry are SignalStain Boost IHC Detection Reagents (Cell Signaling, #8114 and #8125).
Plasmids, shRNAs, and sgRNAs
Three shRNAs targeting human XPO6, a shRNA targeting luciferase (Zhu et al., 2020), and a shRNA targeting human ENL in the lentiviral pLKO.1 vector were purchased from Sigma. XPO6 cDNA in the lentiviral vector pEZ-Lv151 was purchased from GeneCopoeia
(# EX-W2830-Lv151). Silent mutations resistant to shXPO6 #3 (GGAAAGGTTGGTC to AGAGCGCCTCGTG) were introduced by Genewiz between nucleotides 1861-1877 in the XPO6 cDNA (numbering after ATG). Two shRNAs targeting human Pfn1 and a scrambled
shCTRL were cloned in the lentiviral pFLRu-FH vector (Diamond et al., 2015). Silent mutations resistant to shPFN1 #1 and #2 were
introduced in human Pfn1 cDNA by QuickChange: AGC to TCG (nucleotide 253-255) and TTG to CTC (nucleotide 367-369). Paired
guide RNAs specific for human XPO6 gene used with Cas9 (D10A) nickase (Cas9n) were designed using E-CRISP (http://www.
e-crisp.org/E-CRISP/). Oligonucleotides for four pairs of sgRNAs were synthesized, each pair consisting of two annealed oligonucleotides whose target sequences in XPO6 are % 20 base pairs apart. Following oligo annealing, they were inserted into the BbsI sites of
the pSpCas9n(BB)-2A-Puro vector (PX462, Addgene 48141) (Ran et al., 2013). Single guide RNAs for human XPO6 used with wildtype Cas9 were similarly designed, and cloned into the BsmBI site in the lentiCRISPRv2.0 vector (Addgene #52961).
CRISPR/Cas9 editing
For gene editing with the Cas9(D10A) nickase, MDA-MB-231 cells were transfected at 80%–90% confluence in 24-well plates with
1.0mg pSpCas9n(BB)-2A-Puro (expressing Cas9n) alone or individual pairs of XPO6-targeting gRNAs (#1-4) in the same vector (0.5/
0.5mg) with 3ml lipofectamine 2000. Transfected cells were treated with 1mg/ml puromycin for 3-4 days till the untransfected cells died
off. To obtain single clones, pooled cells were diluted to less than 1 cell per 100ml, and 100ml were plated in each well in a 96-well plate
to minimize the likelihood of having > 1 cell per well. Visually confirmed single cells were expanded, confirmed for XPO6 loss, and
used for further experiments. For gene editing with wild-type Cas9, MDA-MB-231 and MCF-7 cells were infected with lentiviral particles consisting of empty lentiCRISPRv2 or the same vector with individual XPO6-targeting sgRNAs. Viral production has been
described previously (Diamond et al., 2015).
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In vitro growth assays
Proliferation assays were performed by seeding approximately 500 cells/well in 96-well plates, followed by quantification by Alamar
blue assay on a fluorescence plate reader on day 1 and subsequent time points as indicated in the specific experiments. Relative
effects of shXPO6 knockdown were expressed as % decrease in the growth rates (day n/day 1) of shXPO6-infeceted cells relative
to shLUC-infected cells. Colony formation assays were performed by seeding approximately 500 cells/well in 6-well plates (or proportionally in 12-well or 24-well plates) and cultured for 9-12 days in the absence or presence of different drugs. Cells were quantified
by Alamar blue prior to fixation with 4% paraformaldehyde for 15min and staining with 0.005% crystal violet for 2h. Colonies were
imaged and quantified for percentages of occupied areas in the wells by ImageJ.
Cell cycle analysis
Standard double thymidine block (2mM thymidine, 18hr first block, 9hr release, 16hr second block) and DNA content analysis by
propidium iodide staining and flow cytometry were conducted. Cell cycle analysis was performed using the univariate Watson model
of FlowJo.
Co-immunoprecipitation and mass spectrometry
Nuclear lysates of approximately 20 3 106 MDA-MB-231 cells were prepared using the NE-PER Nuclear and Cytoplasmic Extraction
kit (Thermo Scientific, PI78833) according to the manufacturer’s protocol. Nuclear lysates were diluted 2x with 10mM Tris-HCl, pH
7.4 in 0.5% Triton X-100, 1x protease (#A32955, ThermoFisher) and phosphatase (#A32957, ThermoFisher) inhibitors, quantified by
the Bradford assay, and equal amounts were mixed with 50ml GFP-Trap agarose beads (Cat # gta-20, Chromotek) to capture YFP
and YFP-tagged NLS-Pfn1(WT versus S137D). After binding at 4 C for 4 hr, beads were washed four times with 10mM Tris-HCl, pH
7.4, 150mM NaCl, 0.5% Triton X-100. Proteins were eluted by SDS sample buffer and subjected to filter-aided sample preparation
(FASP) (Erde et al., 2014; Wi
sniewski et al., 2009) and trypsin digestion. Briefly, 30 ml samples were mixed with 200 ml UA buffer consisting of 8M urea (Sigma, U5128) in 0.1M Tris-HCl, pH 8.5, and added to Microcon YM-30 filter units (Millipore, MRCF0R030). Samples were spun for 15 min at 14,000 x g and washed twice with 100 ml UA buffer by centrifugation at the same speed for the same
length of time. 100 mL of 50 mM iodoacetamide (freshly dissolved in UA buffer) were added, incubated for 20 min at 20 C in the dark.
Samples were centrifuged at 14,000 x g for 10 min, washed twice with 100 ml UA buffer, and 60 mL of sequencing-grade trypsin
(Sigma, #11418025001) (200-400 ng total) in 50mM ammonium bicarbonate was added to the filter units. Following overnight digestion at 37 C, samples were collected by centrifugation at 14,000 x g for 10 min. 50 ml of 0.5M NaCl was added to the filters, centrifuged
at 14,000 x g for 10 min. Pooled eluates were acidified to 5% formic acid (FA), cleaned up by C18 zip-tips (# ZTC18S096, Millipore,
and resuspended in 15 ml 1% formic acid/1% acetonitrile.
Samples were analyzed by reverse-phase liquid chromatography-electrospray ionization-MS/MS using an Eksigent cHiPLC
Nanoflex microchip system connected to a quadrupole time-of-flight TripleTOF 5600 mass spectrometer (ABSCIEX). The Nanoflex
system uses replaceable microfluidic traps and columns packed with ChromXP C18 (200um ID x 15cm, 3 mm particle, 120 Å) for online trapping, desalting, and analytical separations. Solvents composed of water/acetonitrile/formic acid (A, 100/0/0.1%; B, 0/100/
0.1%). A 200 ng to 1mg portion of sample was loaded (typically, 2-10 ml of sample was injected) into column with 98% mobile phase A.
After online trapping, peptide mixtures were eluted into analytical column at a flow rate of 800 nL/min using the following gradient: (1)
starting at 2% solvent B; (2) 2%–5% solvent B from 0 to 12 min; (3) 5%–22% solvent B from 12 to 120 min; (4) 22%–30% solvent B
from 120 to 150 min; (5) 30%–80% solvent from 150 to 165 min; and finally 80%(vol/vol) solvent from 165 to 169 min with a total run
time of 180 min including mobile phase equilibration. The LC column was maintained at 35 C during the run. For Data dependent
acquisitions, mass spectra and tandem mass spectra were recorded in positive-ion and high-sensitivity mode. The nanospray needle
voltage was typically 3,800 V. After acquisition of each sample, TOF MS spectra and TOF MS/MS spectra were automatically calibrated during dynamic LC-MS and MS/MS auto calibration acquisitions by injecting 50 fmol b-galactosidase. For collision-induced
dissociation tandem MS (CID-MS/MS), the mass window for precursor ion selection of the quadrupole mass analyzer was set to ± 1
m/z. The precursor ions were fragmented in a collision cell using nitrogen as the collision gas. Advanced information-dependent
acquisition (IDA) was used for MS/MS collection on the TripleTOF 5600 to obtain MS/MS spectra for the 20 most abundant parent
ions following each survey MS1 scan (allowing typically for 80 ms acquisition time per each MS/MS). Dynamic exclusion features
were set to an exclusion mass width of 50 mDa and an exclusion duration of 30 s.
Protein identification and MS1 quantification was performed with MaxQuant (Cox and Mann, 2008) against the UniProt Human
Reference Proteome. The MS/MS spectra were searched with fixed modification of Carbamidomethyl-Cysteine, variable modifications of oxidation (M), acetylation (protein N-term). Search parameters were set to an initial precursor ion tolerance of 0.07 Da, MS/
MS tolerance at 40 ppm and requiring strict tryptic specificity with a maximum of two missed cleavages. The minimum required peptide length was set to seven amino acids. Peptide identification FDR was set at 1%.
Co-immunoprecipitation and western blot
For MCF-7 cells expressing YFP and NLS-YFP-Pfn1(WT and S137D), nuclear extracts were prepared using a modified Stillman protocol (Méndez and Stillman, 2000). Briefly, approximately 5 3 106 cells were lysed with 200 ml hypotonic buffer A (10 mM HEPES, pH
7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M Sucrose, 10% Glycerol, 1 mM DTT, 0.1% Triton X-100, Protease and phosphatase inhibitor
cocktails) for 15min on ice, and centrifuged at 1,300 g for 5 min. After removing cytosol, nuclei were washed once with buffer A
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without Triton X-100, and lysed with 200 ml nuclear buffer (10mM HEPES, pH 7.0, 200mM NaCl, 1mM EDTA, 0.5% NP-40, and protease-inhibitor cocktail) for 10 min on ice followed by centrifugation at 13,000 g for 10 min. Clarified nuclear lysates were incubated
with 2 mg of the GFP antibody (DSHB, #12E6) overnight at 4 C with rotation and mixed with 30 mL of the protein G beads (CST,
#9007S) at 4 C for 1-2 hr. The beads were then washed 3-5 times with IP buffer (40 mM Tris-Cl, pH 7.5, 150 mM NaCl, 2mM
EDTA, 0.5% Triton X-100, 10% glycerol, and 1 mM DTT), and heated at 95 C in SDS sample buffer for 5 min. For parental and shLUC
or shENL-infected MCF-7 cells, approximately 5 3 106 cells were lysed with 800ul RIPA buffer (EMD Millpore, 20-188) and centrifuged at > 15,000 g for 10 min. 350ul of clarified lysates were incubated for 3 hr at 4 C with 20 mL of protein G magnetic Dynabeads
(Thermo Fisher, 10004D), and 3 mg of normal IgG, ENL, or Cyclin T1 antibodies. Beads were washed 6 times with cold PBS + 0.02%
Tween-20, followed by heating in SDS sample buffer. All samples were subsequently analyzed by SDS-PAGE and western blot
analysis.
For analyzing proteins in cell lysates by western blot, lysates were prepared using RIPA buffer (CST, #9806) supplemented with
protease and phosphatase inhibitors and clarified by centrifugation at 15,000 g for 10min. After normalization using the Quick Start
Bradford 1x Dye Reagent (Bio-Rad, #5000205), 1-10 mg denatured proteins were analyzed by SDS-PAGE and transferred to nitrocellulose membrane (Santa Cruz, sc-3718). Primary antibodies were incubated overnight at 4 C in TBS/0.1% Tween-20 containing
5% bovine serum albumin. Secondary antibodies were incubated at room temperature for 1-2 hr. Proteins were developed using the
SuperSignal West Dura Extended Duration Substrate (34075, ThermoFisher) or West Femto Maximum Sensitivity Substrate (34096,
ThermoFisher), and imaged on a Gel Doc XR imaging system (Bio-Rad). Band intensities were quantified by ImageLab.
Size exclusion chromatography
Nuclei from 15-20 3 106 MDA-MB-231 cells were prepared as described above (under immunoprecipitation and western blot) using a
modified Stillman protocol, and lysed in RIPA buffer. Following sonication and clarification, nuclear extracts were applied to a RIPAequilibrated ENRICH 650 gel filtration column (Bio-Rad) for size exclusion separation. RIPA buffer was used to elute the proteins with
a flow rate of 0.5 mL per minute. Fractions were collected, denatured in SDS sample buffer, and analyzed by western blot.
BrdU labeling
MCF-7 and MDA-MB-231 cells were incubated with growth media containing 10 mM BrdU for 1 hr and 30 min respectively at 37 C in
the CO2 incubator. Cells were permeabilized by PBS/0.1% Triton X-100, denatured by 2M HCl for 30 min and neutralized by 0.1M
sodium tetraborate for 2 min. Primary anti-Brdu antibody (1:200) and Alexa 488-conjugated secondary anti-mouse IgG (1:1000) were
used for the immunofluorescence staining. Propidium Iodide (PI) (20 mg/ml) was used for nuclear staining.
Immunofluorescence staining, cell imaging, and nuclear/cytoplasmic intensity analysis
1x 104 MCF-7 and MDA-MB-231 cells were seeded in 96-well plates, fixed with 4% para-formaldehyde for 15min, washed with PBS,
permeabilized by PBS/0.1% Triton X-100 for 10 min, blocked for 30 min in 2% BSA/2% normal goat serum in PBS/0.1% Tween-20,
and incubated with rabbit anti-Pfn1 antibody (1:1000) in the blocking buffer overnight at 4 C. Cells were washed three times with
PBS/0.1% Tween-20, incubated with Alexa 488-conjugated goat anti-rabbit secondary antibody (Invitrogen #A-11008, 1:1000)
and DAPI for 1hr at room temperature, and washed three times with PBS.
Cell lines expressing YFP-Pfn1 or YFP-actin were grown in 96-well plates, fixed for 15min by 4% para-formaldehyde, washed and
permeabilized as above, counterstained with DAPI, followed by PBS wash.
Imaging was done on an inverted epifluorescence microscope (Olympus IX70) using a 20x objective and CellSens as the acquisition software. High resolution images were captured by choosing the pixel shift function of the camera at the highest setting
(4140 3 3096). ImageJ was used for merging and quantifying nuclear and cytoplasmic fluorescence by the Intensity Ratio Nuclei
Cytoplasm Tool macros. 500-1000 cells were analyzed per experiment.
Immunohistochemistry
5 mm formalin-fixed and paraffin-embedded tumor tissues were subjected to standard IHC protocols. Briefly, tissues were rehydrated through serial washes with xylene and ethanol (100%, 95%, 80%, and 70%). Antigen was retrieved by heating tissues in
Target Retrieval Solution Citrate pH 6.0 (Dako, #S2369) for 20 min followed by quenching with 3mM hydrogen peroxide for
10 min. After washing with TBST (TBS/0.1% Tween-20) and blocking with 5% normal goat serum in TBST for 1 hr at room temperature, tissues were incubated with primary antibodies (Ki67, 1:500; p-Rb(Ser795), 1:500) in blocking buffer at 4 C overnight, washed
with TBST, incubated with HRP-conjugated secondary antibodies for 2 hr at room temperature, washed with TBST, and developed
using the DAB peroxidase substrate kit (Vector Laboratories, #SK-4105).
qRT-PCR
Total RNAs of cells grown in 12-well or 6-well plates were isolated using 250 or 500 ml TRIzol (Invitrogen) according to manufacturer’s instruction. Total RNAs from tumor samples stored in RNAlater solution was isolated the same way. Residual DNA was
digested with RNase-free DNase I (1 mg RNA /1 U enzyme) (ThermoFisher) for 37 C for 30 min. Complementary DNAs were synthesized from 2 mg RNA using the high capacity reverse transcription kit (4368814, ThermoFisher), and quantitative PCR was performed using the PowerUP SYBR Green Master Mix (A25743, Fisher Scientific) in accordance with the manufacturer’s instruction
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on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Relative mRNA levels for each gene of interest were obtained by
normalizing to GAPDH mRNA levels using the comparative cycle threshold (Ct) method. Primers were designed using Primer-Blast
at NCBI or based on published papers (Erb et al., 2017; Kim et al., 2013; McLaughlin-Drubin et al., 2011; Rengasamy et al., 2017;
Struntz et al., 2019).
ChIP-qPCR
1-2 x107 cells were cross-linked with 1% formaldehyde for 10 min, quenched with 125mM glycine for 5 min, washed twice with
cold PBS, and collected by scraping and centrifugation at 1,000 g for 5 min. Cells were resuspended in 750 ml lysis buffer
(50mM Tris-HCl, pH 8.0, 10mM EDTA, 1% SDS, protease inhibitors), and sonicated using a Bioruptor Sonicator (Diagenode).
Samples were centrifuged at 12,000 rpm for 10 min at 4 C, and supernatants containing 25 mg total DNA were diluted 10 times
with IP buffer (16.7 mM Tris-HCl pH 8.0, 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100) and mixed with 2-4 mg
antibodies overnight at 4 C. 20-60 ml protein G-conjugated dynabeads (10003D, Thermo Fisher) were added and incubated for
2 hr at 4 C, washed three times with 20mM Tris-HCl pH 8.0, 150 mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS, followed
by one final wash with the same buffer with 500mM NaCl. DNAs were eluted from beads twice with 200 ml elution buffer (100mM
NaHCO3, 1% SDS) each time for 15 min at room temperature, and the eluates were combined. NaCl was added to the DNAs at
a final concentration of 0.3M, and samples were incubated at 65 C overnight to de-crosslink. 20 mg/ml proteinase K was added
and incubated at 45 C for 2 hr. DNAs were extracted by phenol/chloroform (PI17909, Fisher Scientific), washed with 70%
ethanol, dried, and resuspended in 40 ml water. Quantitative PCR was performed as described for qRT-PCR. The comparative
cycle threshold (Ct) method was used to determine enrichment relative to the level of input DNA (2%) or non-specific IgG
control.
RNA-seq
RNA was extracted from 2 3 106 MCF-7 cells using the RNeasy Mini Kit as per the manufacturer’s protocol (QIAGEN). Two biological replicates were included for each experimental condition. Sample quality was assessed using Agilent BioAnalyzer. Samples
were prepared according to library kit manufacturer’s protocol, indexed, pooled, and sequenced on an Illumina NovaSeq.
QUANTIFICATION AND STATISTICAL ANALYSIS
TCGA gene expression analyses
TCGA RNA-seq data (rnaseqv2_unc_edu_Level_3_RSEM_genes_normalized_data for all cancer types) were downloaded from FireBrowse. These gene-level data had been previously quantified and normalized by TCGA with the RNASeqV2 pipeline using RNA-Seq
by Expectation Maximization (RSEM) (Li and Dewey, 2011). Data were analyzed by Python 3.8 for statistical significance with the
Scipy, Pingouin, and Scikit Posthocs packages. Graphs were generated by GraphPad Prism 7.0. For Figures 1A and S6A and Tables
S1A, S1B, and S1D, Mann-Whitney U non-parametric tests were used to calculate the statistical significance of the difference in
XPO6 and Pfn1 mRNA levels between unmatched tumor and normal tissue samples. For Figures 1B and S6B and Table S1C, Wilcoxon Signed Rank non-parametric tests were used to calculate the statistical significance of the difference in XPO6 and Pfn1 mRNA
levels between paired tumor and adjacent normal samples. For Figure S1A, a non-parametric one-way ANOVA (Kruskal-Wallis) with
Dunn’s multiple comparison test was performed to analyze the difference in XPO6 mRNA levels among breast cancer PAM50 subtypes and normal tissues. For Figure 6G and Table S3, correlations between MYC mRNA level and those of XPO6, BRD4, and NCL in
the various TCGA datasets were analyzed using Spearman’s rank correlation coefficient. For hypothesis testing involving multiple
comparisons, false discovery rate was controlled by using the Benjamini-Hochberg method. P and q values less than 0.05 were
considered significant.
Combined TCGA/GTEx gene expression analyses
Normalized, batch effect-corrected RNA-seq data from a study combining TCGA and GTEx datasets were retrieved from Figshare
(https://figshare.com/articles/dataset/Data_record_3/5330593). For each of the 17 cancer types in Table S1B, RNA expression from
TCGA tumor samples was compared to expression from a combined set of TCGA adjacent healthy samples and tissue-matching
GTEx normal samples using Mann-Whitney U non-parametric tests. The Benjamini-Hochberg method was used to adjust p values.
Data processing and hypothesis testing were performed using Python.
CPTAC proteomic data analysis
For Figures S1D and S6D, processed mass spectrometry data of 125 tumors and 18 normal samples in the Clinical Proteomic Tumor
Analysis Consortium (CPTAC) Breast Cancer Confirmatory Study were downloaded from the CPTAC Data Portal (https://
cptac-data-portal.georgetown.edu/). Raw data had been processed through the CPTAC Common Data Analysis Pipeline (CDAP)
and provided as log2 transformed normalized values against a common pool of reference samples. Statistical significance of the difference in protein abundance between tumor and normal samples were calculated using the Mann-Whitney U or Wilcoxon Signed
Rank non-parametric tests for unpaired or paired samples by GraphPad Prism 7.0. P values less than 0.05 were considered
significant.

Cell Reports 34, 108749, February 16, 2021 e7

ll
OPEN ACCESS

Article

Kaplan-Meier survival analyses
Kaplan-Meier survival outcome analysis was performed using KM plotter (http://kmplot.com). For overall survival analysis of various
TCGA datasets as undivided cohorts (Figures 1E and S6E) or stage-defined sub-cohorts (Figures 1F, 2A, and S6E), RNA-seq data
and clinical information hosted by KM plotter were used. For overall and progression-free survival analysis of TCGA breast cancer
patients divided based on lymph node and ER status (Figures S2B–S2D and S6F), RNA-seq data were downloaded from FireBrowse
and curated clinical data (Liu et al., 2018) were downloaded from the UCSC Xena Browser, and then imported into KM plotter for
statistical analysis and graph generation using the web-based custom plotting function. For relapse-free survival of breast cancer
patients in the GEO and EGA datasets (Figures S2E–S2H, S6G, and S6H), gene chip data and clinical information hosted at KM
plotter were used. For overall survival analysis against proteomic data (Figures 1G and S6I), a published study (Tang et al., 2018)
consisting of mass spectrometry data and clinical information of 65 breast cancer patients available at KM plotter was used. For
all analyses, median cutoff was chosen to split cohorts evenly into subgroups with high versus low mRNA or protein levels of
XPO6 and Pfn1. For analyses using gene chip data, JetSet best probe sets for XPO6 and Pfn1 (Affimetrix ID 211982 and 200634)
were selected. Log-rank tests were used to calculate p values.
RNA-seq analysis
Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a custom python demultiplexing program with a
maximum of one mismatch in the indexing read. RNA-seq reads were aligned to the Ensembl release 76 primary assembly with STAR
version 2.5.1a. Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version
1.4.6-p5. All gene counts were imported into the R/Bioconductor package EdgeR and TMM normalization size factors were calculated to adjust for samples for differences in library size. Ribosomal genes and genes not expressed in the smallest group size minus
one sample greater than one count-per-million were excluded from further analysis. The TMM size factors and the matrix of counts
were imported into the R/Bioconductor package Limma. Weighted likelihoods based on the observed mean-variance relationship of
every gene and sample were then calculated for all samples with the voomWithQualityWeights. Differential expression analysis was
then performed to analyze for differences between shXPO6 and shLUC-infected cells expressing XPO6(WT) or XPO6(RNAi-Res), and
the results were filtered for only those genes with Benjamini-Hochberg false-discovery rate adjusted p values less than or equal to
0.05. For each contrast extracted with Limma, global perturbations in known Gene Ontology (GO) terms, MSigDb, and KEGG pathways were detected using the R/Bioconductor package GAGE to test for changes in expression of the reported log 2 fold-changes
reported by Limma in each term versus the background log 2 fold-changes of all genes found outside the respective term. A subset of
significantly enriched gene sets were plotted using R/ggplot2. Gene set enrichment analysis (GSEA) was performed using the GSEA
software (4.0) (Subramanian et al., 2005). To visualize RNA-seq tracks for representative genes, 2-3 significantly downregulated
genes in XPO6 knockdown cells expressing XPO6(WT) but not XPO6(RNAi-res) cells were chosen from each gene set. RNA-seq
BAM files were converted to the BigWig format using DeepTools and sequencing data were normalized using the Reads Per Kilobase
per Million mapped reads (RPKM) method. These normalized data were loaded into the Integrated Genome Viewer (Robinson et al.,
2011) and replicates for each sample were summed together.
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Supplementary Figures

Fig.S1 XPO6 upregulation in breast cancer, related to Figure 1.
(A) XPO6 mRNA levels in TCGA breast tumor samples divided into distinct molecular subtypes based on
PAM50 classification. Non-tumor controls are adjacent healthy tissue samples. Whiskers extent to the 5-95
percentiles. P values were based on non-parametric one-way ANOVA (Kruskal-Wallis) with Dunn's post-hoc
test. (B) XPO6 mRNA levels in matched tumor and adjacent normal tissues of 112 breast cancer patients in the
TCGA dataset divided into distinct molecular subtypes based on PAM50 classification. (C) XPO6 mRNA levels
in TCGA breast tumor samples divided based on stages. Whiskers extend to the 5-95 percentiles. (D) Protein
levels of selected nuclear exportins (including XPO6) in 125 breast tumor and 18 normal breast tissue samples
in the CPTAC confirmatory cohort detected by quantitative mass spectrometry analysis. P values were based on
the Mann-Whitney U non-parametric test. Note: XPO6 was undetectable in normal breast tissues.

Fig.S2 Association of XPO6 mRNA level with breast cancer survival, related to Figure 1.
(A) Univariate Kaplan-Meier analysis of the association between XPO6 mRNA level and overall survival (OS)
of TCGA breast cancer patients separated by stages. (B-C) Univariate Kaplan-Meier analysis of the association
between XPO6 mRNA level and OS of TCGA breast cancer patients separated by the status of lymph node

spread (B) and ER positivity (C). (D) Univariate Kaplan-Meier analysis of the association between XPO6
mRNA level and progression-free survival (PFS) of TCGA breast cancer patients as a while cohort or separated
by lymph node status. (E) Univariate Kaplan-Meier analysis of the association between XPO6 mRNA level and
relapse-free survival (RFS) of breast cancer patients in the combined GEO and EGA datasets (35 in total)
separated by lymph node status. (F-G) Univariate Kaplan-Meier analysis of the association between XPO6
mRNA level and RFS of breast cancer patients in the GSE21653 dataset consisting of 227 early-stage breast
cancer patients separated by lymph node status (F) or ER positivity (G). (H) Univariate Kaplan-Meier analysis
of the association between XPO6 mRNA level and RFS of ER-positive, tamoxifen-treated, early-stage breast
cancer patients (n=75) in the GSE9195 (also known as GUYT2) dataset (Loi et al., 2008). All the analyses were
performed using KM plotter with median cutoff to evenly divide patient cohorts into high and low XPO6
subgroups. For GEO/EGA datasets, JetSet best probe set for human XPO6 gene (211982) was selected. P
values were based on the log-rank test.

Fig.S3 Effect of XPO6 knockdown on the growth of soft tissue sarcoma cell lines, related to Figure 2.
(A-B) Soft tissue sarcoma cell lines SK-UT-1 and SK-LM-1 were infected with shLUC or shXPO6 #1 and 3,
and subjected to colony formation assays. Western blot was performed to confirm XPO6 knockdown efficiency
with tubulin as the loading control. Colony areas were quantified by ImageJ, and relative effects of XPO6
knockdown were expressed as fold changes in colony areas of shXPO6-infected cells over those infected with
shLUC. Data are mean ± SD of one representative experiment (quadruplicates per condition). P values were
based on unpaired t-test by comparing shXPO6 infected cells to those with shLUC. Results were confirmed
three times independently. (C) Western blot analysis showing overexpression of XPO6 lacking (WT) or
containing silent mutations (RNAi-Res) in MCF-7 cells by lentiviral infection. Vector-infected cells show
endogenous level of XPO6. GAPDH was blotted as the loading control. **, P<0.01, ****; P<0.0001.

Fig. S4 Effect of XPO6 knockout by CRISPR/Cas9 on MDA-MB-231 cell cycle progression and growth in
vitro, related to Figure 2.
(A) MDA-MB-231 cells were transiently transfected with Cas9n alone or together with four pairs of gRNAs
targeting different regions of human XPO6. Cells were selected with puromycin for three days, expanded in its
absence, and analyzed by Western blot for XPO6 and GAPDH. They were subsequently compared for colony
formation abilities. (B) Single clones selected from Cas9n or Cas9n/gRNAs #4-transfected MDA-MB-231 cells
were subjected to Western blot analysis and colony formation assays. (C) Single clones selected from
Cas9n/gRNAs #2-transfected MDA-MB-231 cells were subjected to Western blot analysis and colony
formation assays as compared to pooled Cas9n only control cells. For A-C, data are mean ± SD of a
representative experiment (triplicates per condition). P values for A and C were based on one-way ANOVA
with Dunnett’s multiple comparison tests. P values for B were based on one-way ANOVA with Tukey’s
multiple comparison tests. Results were confirmed three times independently. (D) Pooled MDA-MB-231 cells
from (A) were pulsed and stained for BrdU. Total cells were stained by propidium iodide. Percentages of BrdUpositive cells and p values were calculated as in Fig.2F. (E) Clones of MDA-MB-231 cells transfected with

Cas9n or Cas9n/gRNA #2 and #4 as in (B-C) were subjected to DNA content analysis after double thymidine
block and release, as described in 2G. For all the statistical analyses, **, p<0.01; ***, p<0.001; ****, p<0.0001.

Fig.S5 Effect of XPO6 loss on subcellular localization of Pfn1 and actin in breast epithelial cell lines,
related to Figure.4.
(A) MCF-7 and MDA-MB-231 cells were infected with control or sgXPO6-expressing lentiviruses and
subjected to immunofluorescence staining for endogenous Pfn1 and nuclear counterstaining with DAPI.
Representative images were shown to the left. More than >1000 cells per condition were analyzed by ImageJ to
quantitatively compare relative Pfn1 intensity in the nucleus vs. cytoplasm (ratio). One-way ANOVA and
Dunnett’s multiple comparison tests (sgXPO6 vs. control) were used to calculate p values. Scale bars, 20µm.

(B) Western blot showing relative expression level of exogenous YFP-Pfn1 compared to endogenous Pfn1 in
various cell lines. (C) MCF-7 cells expressing YFP-Pfn1 and XPO6 (WT) or XPO6 (RNAi-resistant) were
infected with shLUC or shXPO6 #3, and analyzed by direct fluorescence after fixation and DAPI staining. Scale
bars, 20µm. (D) YFP-Pfn1-expressing MCF-10A, MDA-MB-231, and T47D cells were infected with shLUC or
shXPO6 (#3) and imaged for YFP-Pfn1 and DAPI as described in C. Scale bars, 20µm. (E) MCF-7 cells were
sequentially infected with shLUC or shXPO6 (#3) and shCTRL or shPFN1 (#2), followed by transient
transfection with YFP-actin. YFP-actin-positive cells were imaged by direct fluorescence after fixation and
DAPI staining. Effects of XPO6 loss on YFP-Pfn1 and YFP-actin subcellular localization in C-E were
confirmed by more than three independent experiments, each consisting of >100 cells. Scale bars 20µm. (F)
MCF-7 cell growth rates in 2D culture (Day 11/Day 1 ratio) after single or double knockdown of XPO6 and
Pfn1, related to Fig.4B. (G) Growth rates of Pfn1-null mouse chondrocytes re-infected with empty vector or
untagged Pfn1 in 2D culture (ratio Day 11/Day 1), related to Fig.4C. (H) Pfn1-null mouse chondrocytes were
re-infected with YFP, YFP-Pfn1(WT), or YFP-NES-Pfn1(WT), and subjected to Western blot and 2D growth
assay as described in F-G, related to Fig.4D. Expression levels of transduced Pfn1 fusion proteins were
compared to endogenous Pfn1 in wild type mouse chondrocytes. Data in F-H are mean ± SEM of a
representative experiment (sextuplicates per condition). P values in F-H were based on one-way ANOVA and
Tukey’s multiple comparison tests. Results were confirmed by three independent experiments. For all the
statistical analyses, *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

Fig. S6 Pfn1 mRNA and protein level in breast cancer, related to Figure 4.
(A) TCGA cohorts in which Pfn1 mRNA level is significantly altered relative to normal tissues. Whiskers
represent min-max. Mann-Whitney U non-parametric test was used to calculate statistical significance (values
in Table S1D). (B) Pfn1 mRNA levels of 112 TCGA breast tumors compared with their adjacent normal tissues.

P value is based on Wilcoxon Signed Rank non-parametric test. (C) Western blot analysis for Pfn1 in
untransformed and transformed breast epithelial cell lines (same panel as in Fig.1D). Actin and PELP1 were
used as cytoplasmic and nuclear control proteins. (D) Pfn1 protein level in the CPTAC confirmatory breast
tumor cohort detected by quantitative mass spectrometry analysis. Unpaired comparison between the 125 breast
tumors and 18 normal tissues was shown to the left. Paired comparison of the 18 breast tumors with their
adjacent normal tissues was shown to the right. P values were based on Mann-Whitney U non-parametric test
(unpaired comparison) and Wilcoxon Signed Rank non-parametric test (paired comparison). (E) Univariate
Kaplan-Meier analysis of the association between Pfn1 mRNA level and the overall survival (OS) of breast
cancer patients in the TCGA dataset. Analysis was performed by KM plotter for the entire cohort or stage II
patients. (F) Univariate Kaplan-Meier analysis of the association between Pfn1 mRNA level and the overall
survival (OS) of breast cancer patients in the TCGA dataset divided based on lymph node status. (G) Univariate
Kaplan-Meier analysis of the association between Pfn1 mRNA level and the overall survival (RFS) of breast
cancer patients in the combined GEO and EGA datasets divided by lymph node. (H) Univariate Kaplan-Meier
analysis of the association between Pfn1 mRNA level and the overall survival (RFS) of breast cancer patients in
the GSE21653 dataset divided by lymph node status. (I) Univariate Kaplan-Meier analysis of the association
between Pfn1 protein level and the overall survival (OS) of a cohort of 65 breast cancer patients using KM
plotter. For (E-I), median cutoff was used for patient separation. P values were based on log-rank test.

Fig.S7 Inhibition of SEC function by nuclear Pfn1, related to Figure 6.
(A) Direct fluorescence imaging of MCF-7 cells expressing YFP-tagged NLS-Pfn1(WT or S137D) or NESPfn1(WT). Scale bars, 20µm. (B) RT-qPCR analysis of MYC expression level in different breast epithelial cell
lines expressing YFP, YFP-NLS-Pfn1(WT), or YFP-NLS-Pfn1(S137D). P values were based on unpaired t-test
by comparing NLS-Pfn1(WT or S137D) vs. YFP. (C) RT-qPCR analysis of MYC expression level in different
breast epithelial cell lines infected with shLUC or shXPO6 #3. P values were based on unpaired t-test by
comparing shLUC vs. shXPO6. (D) Distribution of all genes in the TCGA breast cancer dataset based on the
correlation of their mRNA levels with that of MYC. Spearman correlation coefficient was used (, x-axis). Yaxis reflects the number of genes correlating with MYC with a given  value. (E) Chromatin IP using antibodies
against SEC components (ENL, Cyclin T1, Cdk9) and pSer2-Rpb1 from MCF-7 cells infected with vector only
or untagged Pfn1(WT) or Pfn1(S137D), followed by qPCR using MYC primers as in Fig.6H and 6I. Percentages
of input were used for quantification. P values were based on unpaired t-test by comparing Pfn1(WT or S137D)

vs. vector. Western blot and densitometry show the relative expression level of exogenous Pfn1 to endogenous
Pfn1. (F) Chromatin IP using antibodies against ENL, Cyclin T1, and pSer2-Rpb1 from MCF-7 cells stably
expressing Pfn1(WT) or Pfn1(RNAi-Res) and infected with shCTRL or shPFN1 (#1), followed by qPCR using
MYC primers as in (B). Fold enrichment of each target protein over control IgG was used for quantification. P
values were based on unpaired t-test by comparing shPFN1 vs. shCTRL within Pfn1(WT) or Pfn1(RNAi-Res)
cells. For all the statistical analyses, *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

Fig.S8 Transcriptomic effects of XPO6 loss, related to Fig.7.
(A) Gene set enrichment analysis (GSEA) evaluating shXPO6-induced gene expression changes in MCF-7 cells
expressing XPO6(WT) or XPO6(RNAi-R) using the MSigDB hallmark (50 gene sets) database. Shown are
seven significantly enriched hallmark gene sets in addition to the two gene sets shown in Fig.7A (related to
Table S4A). FDR, false discovery rate; NES, normalized enrichment score. (B) Representative gene sets (EZH2
repressed targets bearing H3K27me3) in the curated MSigDB chemical and genetic perturbations (CGP) gene

sets (3302 gene sets) which are significantly enriched in shXPO6-infected XPO6(WT)-expressing MCF-7 cells,
using GAGE analysis. Changes in the XPO6(RNAi-Res)-expressing MCF-7 cells are shown as the control.

Fig.S9 RNA-seq tracks of representative genes in the significantly enriched hallmark gene sets by XPO6
knockdown based GSEA analysis, related to Fig.7 and Fig.S8A. Two representative genes are selected from
each of the nine hallmark gene sets significantly enriched by XPO6 knockdown in MCF-7 cells based on gene
set enrichment analysis (GSEA). RNA-seq reads are shown for all four experimental conditions including
XPO6(WT) and XPO6(RNAi-R) cells infected with shLUC or shXPO6. Each track represents the sum of
RPKM-normalized reads (Y-axis) from two replicate RNA-seq experiments.

Fig.S10 In vitro JQ1-sensitizing effect of XPO6 loss, related to Fig.7.
(A) MDA-MB-231 cells infected with shLUC or two different shXPO6 viruses were treated with DMSO or JQ1
at different concentrations in colony formation assays for 8 days, and quantified by Alamar blue. Relative drug
effect was calculated by dividing JQ1-treated cell numbers by those treated with vehicle. P values were based
on one-way ANOVA and Dunnett’s multiple comparisons by comparing sXPO6 and shLUC at different JQ1
concentrations. (B) MDA-MB-231 cells transfected with Cas9n or Cas9n with two pairs of XPO6-specific
gRNAs were treated with DMSO or JQ1 for 7 days in colony formation assays and quantified by Alamar blue.
Relative drug effects and p values were calculated as in (A). (C) Western blot showing high XPO6 KO
efficiency in the MDA-MB-231 cells before inoculation in mice. (D) Western blot showing largely sustained
XPO6 KO efficiency in the resected tumors. Five tumors from the vehicle groups of control and sgXPO6 mice
were randomly chosen. For all the statistical analyses, *, p<0.05; **, p<0.01; ****, p<0.0001.
Supplementary Tables
Table S2 List of nuclear proteins specifically detected by co-immunoprecipitation and LC-MS to interact
with NLS-Pfn1(WT), related to Fig.5B.
LFQ Intensity
YFP
0

Pfn1
(WT)
5669.3

Pfn1
(S137D)
0

0

3193.4

0

LFQ ratio

LFQ ratio

Pfn1(WT)
vs.
Pfn1(S137D)

Pfn1(WT)
vs. YFP

N/A

N/A

N/A

N/A

Protein ID
(HUGO names)

HIST1H1C;HIST1H1E;
HIST1H1D
SERBP1

PLP motifs
(XPn, n≥5;
X=A, I, L, S, G)

0

2765.7

0

N/A

N/A

ZMYM4

0

2516.6

0

N/A

N/A

SFPQ

0

2323

0

N/A

N/A

NCL

0

2243.7

0

N/A

N/A

U2AF1;U2AF1L4

0

1906.9

0

N/A

N/A

PDLIM5

0

1344.4

0

N/A

N/A

RPL28

0

1190.8

0

N/A

N/A

SEPTIN9

0

1149.3

0

N/A

N/A

YBX1

0

1148.9

0

N/A

N/A

HP1BP3

0

1089.1

0

N/A

N/A

EEF1G

0

1070.6

0

N/A

N/A

AFF4

0

1035.4

0

N/A

N/A

OARD1

0

963.61

0

N/A

N/A

NACC1

0

755.65

0

N/A

N/A

ACYP2

0

678.92

0

N/A

N/A

SDHA

0

653.04

0

N/A

N/A

SPTBN1

0

653.03

0

N/A

N/A

ELL

0

648.88

0

N/A

N/A

NBN

0

561.46

0

N/A

N/A

THOC1

0

556.13

0

N/A

N/A

TPR

0

495.84

0

N/A

N/A

NPM1

0

436.67

0

N/A

N/A

TP53BP1

0

426.69

0

N/A

N/A

TRIP6

0

383.43

0

N/A

N/A

BOD1L1

0

376.2

0

N/A

N/A

USP48

0

299.3

0

N/A

N/A

SEC24B

0

291.88

0

N/A

N/A

0

280.5

0

N/A

N/A

CAMK2D;CAMK2G;
CAMK2B;CAMK2A
RTCB

0

278.72

0

N/A

N/A

DOCK1

520.9

1429.1

0

N/A

2.743521

0

574.58

128.49

4.471788

N/A

1182.2

4379

1546.4

2.831738

3.704111

NONO

0

4116.9

1649.9

2.495242

N/A

TOP1

0

2032.4

900.98

2.255766

N/A

CCNT1 (Cyclin T1)

4440.4

9207.2

5605.6

1.6425

2.073507

0

9049.7

12121

0.746613

N/A

IP5, QP5, GP5

AP6, QP6

SLC9A3R2
MLLT1 (ENL)

GP9

MYH9
PFN1 (Profilin-1)

Table S3 Correlation analysis of MYC mRNA level in TCGA datasets with those of XPO6, BRD4, and
NCL, related to Fig.6G.
Cancer
type
BLCA
BLCA

Case
number
408
408

Gene correlated with MYC

Correlation coefficient ()

Positive correlation between XPO6 and MYC, statistically significant
XPO6
0.352872
BRD4
0.112877

FDR q-values

0.0000
0.0444

BLCA
BRCA
BRCA
BRCA
CESC
CESC
CESC
COAD
COAD
COAD
ESCA
ESCA
ESCA
GBM
GBM
GBM
HNSC
HNSC
HNSC
KIRP
KIRP
KIRP
LGG
LGG
LGG
LUAD
LUAD
LUAD
LUSC
LUSC
LUSC
PAAD
PAAD
PAAD
SARC
SARC
SARC
STAD
STAD
STAD
THYM
THYM
THYM
OV
OV
OV

408
1093
1093
1093
304
304
304
285
285
285
184
184
184
153
153
153
520
520
520
290
290
290
516
516
516
515
515
515
501
501
501
178
178
178
259
259
259
415
415
415
120
120
120
303
303
303

NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL

0.510321
0.152878
0.232964
0.329715
0.307644
0.235313
0.260244
0.254252
0.139062
0.380718
0.29624
0.305099
0.268953
0.227795
0.405643
0.215412
0.288748
0.129335
0.346166
0.386741
0.114534
0.318328
0.337445
0.218876
0.363515
0.10036
0.102506
0.279344
0.208782
0.284897
0.252379
0.242768
0.129126
0.349089
0.181895
-0.00447
0.295661
0.222563
0.027652
0.372324
0.461317
0.098028
0.421488

Positive correlation between XPO6 and MYC, statistically insignificant
XPO6
0.078555
BRD4
0.007782
NCL
0.19199

0.0000
0.0000
0.0000
0.0000
0.0000
0.0001
0.0000
0.0001
0.0382
0.0000
0.0001
0.0001
0.0006
0.0107
0.0000
0.0167
0.0000
0.0078
0.0000
0.0000
0.0893
0.0000
0.0000
0.0000
0.0000
0.0444
0.0400
0.0000
0.0000
0.0000
0.0000
0.0029
0.1387
0.0000
0.0079
0.9464
0.0000
0.0000
0.6611
0.0000
0.0000
0.3731
0.0000
0.2452
0.9275
0.0021

SKCM
SKCM
SKCM
UCEC
UCEC
UCEC
UCS
UCS
UCS
PRAD
PRAD
PRAD
ACC
ACC
ACC
CHOL
CHOL
CHOL
DLBC
DLBC
DLBC
KICH
KICH
KICH
LIHC
LIHC
LIHC
OV
OV
OV

103
103
103
176
176
176
57
57
57
497
497
497
79
79
79
36
36
36
48
48
48
66
66
66
371
371
371
303
303
303

XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL
XPO6
BRD4
NCL

0.155285
0.184719
0.216481
0.10687
0.334733
0.504854
0.154784
0.355847
0.225694
0.082714
0.128944
0.381517
0.129747
0.070058
0.482157
0.166281
0.02677
0.63861
0.070126
0.277681
0.67271
0.012671
0.16969
0.0401
0.016098
-0.08045
0.519352
0.078555
0.007782
0.19199

0.1822
0.1043
0.0522
0.2286
0.0000
0.0000
0.3310
0.0149
0.1434
0.1079
0.0094
0.0000
0.3337
0.6301
0.0000
0.4188
0.9190
0.0001
0.7064
0.0964
0.0000
0.9428
0.2452
0.8155
0.8187
0.1852
0.0000
0.2452
0.9275
0.0021

P-values calculated from the Spearman correlation were subjected to multiple hypothesis correction using the
Benjamini-Hochberg method to generate FDR q-values.

